PEGylated indocyanine dye coupled to paclitaxel prodrug compound and its preparation and application
By designing PEGylated indocyanine dye-coupled paclitaxel prodrug compounds with redox-sensitive bonds, the problems of solubility and toxicity reactions of existing paclitaxel preparations have been solved, and the effect of improving solubility and tumor targeting is achieved. It demonstrated significant cytotoxicity to human breast, gastric and colon cancer cells.
Patent Information
- Application Number
- CN202310022430.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-01-07
- Publication Date
- 2024-11-01
- Estimated Expiration
- 2043-01-07
AI Technical Summary
Existing paclitaxel preparations have low solubility in water and commonly used vehicles such as Cremophor EL lead to toxic reactions and reduce anti-tumor efficacy. Existing nano-formulations also have their own disadvantages, making it difficult to improve solubility and targeting at the same time.
Design a PEGylated indocyanine dye-coupled paclitaxel prodrug compound based on redox-sensitive bond linkage, and covalently binds to the near-infrared indocyanine dye that specifically targets tumor cells through the principle of molecular hybridization, and Coupling of paclitaxel through highly redox-sensitive chemical bonds can form compounds that have both tumor targeting and therapeutic functions.
The solubility and tumor targeting of paclitaxel were improved. Preliminary in vitro experiments showed that the compound had significant cytotoxicity to human breast cancer, gastric cancer and colon cancer cells, and the IC50 value was close to that of paclitaxel, indicating that this design idea has potential.
Smart Images

Figure CN116178700B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of pharmacy, and specifically relates to a tumor-targeting PEGylated indocyanine dye-coupled paclitaxel prodrug compound based on redox-sensitive bond connection, a preparation method thereof, and an application thereof in the preparation of anti-tumor drugs. Background Art
[0002] Paclitaxel (PTX) is a diterpenoid anti-tumor drug that can effectively treat solid tumors such as breast cancer, non-small cell lung cancer, ovarian cancer, and gastric cancer [1,2]. PTX has a unique anti-tumor mechanism that induces and promotes the polymerization of tubulin into microtubules while inhibiting the depolymerization of the formed microtubules. The microtubule bundles cannot connect to the microtubule organizing center, and the mitosis of cancer cells is abnormal or stays in the G2 / M phase, resulting in the inability of cancer cells to replicate and ultimately leading to the death of cancer cells [3,4].
[0003] Although PTX has good anti-tumor effects, its solubility in water is extremely low, with only 0.25 μg dissolved in 1 mL of water[5]. To solve this problem, the first PTX injection on the market, Taxol, was developed. PTX is dissolved in a mixed solvent consisting of the non-ionic surfactant polyoxyethylene castor oil (Cremophor EL) and anhydrous ethanol in equal proportions. Cremophor EL is believed to be related to the common clinical toxic reactions of paclitaxel - allergic reactions, neurotoxicity and nephrotoxicity: when Cremophor EL is degraded in the body, it can cause mast cell degranulation, release histamine, or activate complement to cause severe allergic reactions [6,7]; moreover, Cremophor EL causes swelling of peripheral neurons in animals, release of intracellular granules and demyelination changes in nerve cells, causing neurotoxicity. In addition, it has been recently reported that the use of Cremophor EL in paclitaxel preparations reduces its anti-tumor efficacy [8].
[0004] The defects of PTX have prompted major pharmaceutical companies to continue to develop new PTX preparations. A variety of PTX nanoformulations have been launched, such as paclitaxel liposome preparations Albumin-bound paclitaxel Micellar polymer paclitaxel formulation etc. However, these preparations also have their own disadvantages: Lipusu has similar allergic reactions to Taxol, Abraxane is expensive, and Genexol-PM has neuromuscular toxicity and bone marrow suppression. Therefore, in the study of paclitaxel, in order to improve the solubility of PTX and enhance its tumor targeting, in addition to developing new drug delivery systems, designing paclitaxel prodrugs with improved properties is also another major hotspot in paclitaxel research. Summary of the invention
[0005] The purpose of the present invention is to provide a tumor-targeting PEGylated indocyanine dye-coupled paclitaxel prodrug compound based on redox-sensitive bond connection, a preparation method thereof and an application thereof in the preparation of anti-tumor drugs.
[0006] To achieve the above object, the technical solution of the present invention is:
[0007] A PEGylated indocyanine dye coupled to paclitaxel prodrug compound, the compound is a PEGylated indocyanine dye coupled to paclitaxel prodrug compound having a general formula (I) and a pharmaceutically acceptable salt and solvate thereof:
[0008]
[0009] in:
[0010] R 1 and R 2 may be the same or different and are independently selected from hydrogen, C1-C5 alkyl, C1-C5 alkoxy, sulfonic acid, halogen, phenyl; and, R 1 and / or R 2 It can also form an aryl or heteroaryl group with the adjacent C 1 and / or R 2 With the adjacent C on the phenyl group to form benzo[e]indole);
[0011] X is selected from the following link chains:
[0012]
[0013] Y - It is a halogen anion;
[0014] 1≤m≤5; 2≤p≤6; 1≤n≤45.
[0015] Preferably, the compound is a PEGylated indocyanine dye coupled to paclitaxel prodrug compound represented by general formula (I) and a pharmaceutically acceptable salt or solvate thereof:
[0016] R 1 and R 2 may be the same or different and are independently selected from hydrogen, C1-C3 alkyl, C1-C3 alkoxy, sulfonic acid, halogen, phenyl; and, R 1 and / or R 2 It can also form an aryl or heteroaryl group with the adjacent C 1 and / or R 2 With the adjacent C on the phenyl group to form benzo[e]indole);
[0017] X is selected from the following link chains:
[0018]
[0019] Y - is bromine or iodine;
[0020] 1≤m≤5; 2≤p≤6; 1≤n≤45.
[0021] More preferably, the compound is
[0022] Phenylpropionic acid, β-(benzoylamino)-α-[3-[2-[3-[2-[3-[1-[5-[methoxypolyethylene glycol aminocarbonyl]pentyl]-1,3-dihydro-3,3-dimethyl-2H-indol-2-methylideneethylidene]-2-chloro-1-cyclohexen-1-yl]vinyl]-3,3-dimethyl-3H-indol-1-ylpropylaminocarbonyl]ethyl]thiomethylethylidenethio]propanoyloxy-6,12b-bis(acetoxy)-12- (Benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methylene-1H-cyclodecano[3,4]benzo[1,2-b]oxetan-9-yl ester, [2aR-[2aα,4β,4aβ,6β,9α(αR*,βS*),11α,12α,12aα,12bα]];
[0023] Phenylpropionic acid, β-(benzoylamino)-α-[3-[2-[3-[2-[3-[1-[5-[methoxypolyethylene glycol aminocarbonyl]pentyl]-1,3-dihydro-3,3-dimethyl-2H-indol-2-methylideneethyl]-2-chloro-1-cyclohexen-1-yl]vinyl]-3,3-dimethyl-3H-indol-1-ylpropylaminocarbonyl]ethyl]thio]propanoyloxy-6,12b-bis(acetoxy)-12-(benzoyl)propanoic acid oxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methylene-1H-cyclodecano[3,4]benzo[1,2-b]oxetan-9-yl ester, [2aR-[2aα,4β,4aβ,6β,9α(αR*,βS*),11α,12α,12aα,12bα]];
[0024] Phenylpropionic acid, β-(benzoylamino)-α-[3-[2-[3-[2-[3-[1-[5-[methoxypolyethylene glycol aminocarbonyl]pentyl]-1,3-dihydro-3,3-dimethyl-2H-indol-2-methylidene]ethylidene]-2-chloro-1-cyclohexen-1-yl]vinyl]-3,3-dimethyl-3H-indol-1-ylpropylaminocarbonyl]ethyl]disulfide]propionyloxy-6,12b-bis(acetyloxy)-12-(phenylpropionic acid) Acyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methylene-1H-cyclodecano[3,4]benzo[1,2-b]oxetan-9-yl ester, [2aR-[2aα,4β,4aβ,6β,9α(αR*,βS*),11α,12α,12aα,12bα]];
[0025] Phenylpropionic acid, β-(benzoylamino)-α-[4-[3-[3-[2-[3-[1-[5-[methoxypolyethylene glycol aminocarbonyl]pentyl]-1,3-dihydro-3,3-dimethyl-2H-indol-2-methylidene]ethylidene]-2-chloro-1-cyclohexen-1-yl]vinyl]-3,3-dimethyl-3H-indol-1-ylpropylaminocarbonyl]ethyl]disulfide]butyryloxy-6,12b-bis(acetyloxy)-12-(phenylpropionic acid) Acyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methylene-1H-cyclodecano[3,4]benzo[1,2-b]oxetan-9-yl ester, [2aR-[2aα,4β,4aβ,6β,9α(αR*,βS*),11α,12α,12aα,12bα]];
[0026] Phenylpropionic acid, β-(benzoylamino)-α-[3-[2-[3-[1-[5-[methoxypolyethylene glycol aminocarbonyl]pentyl]-1,3-dihydro-3,3-dimethyl-2H-indol-2-methylidene]ethylidene]-2-chloro-1-cyclohexen-1-yl]vinyl]-3,3-dimethyl-5-sulfonic acid-3H-indol-1-ylpropylaminocarbonyl]methylthio]acetoxy-6,12b-bis(acetoxy)-12-(benzoyl)propionic acid oxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methylene-1H-cyclodecano[3,4]benzo[1,2-b]oxetan-9-yl ester, [2aR-[2aα,4β,4aβ,6β,9α(αR*,βS*),11α,12α,12aα,12bα]];
[0027] Phenylpropionic acid, β-(benzoylamino)-α-[3-[2-[3-[1-[5-[methoxypolyethylene glycol aminocarbonyl]pentyl]-1,3-dihydro-3,3-dimethyl-2H-indol-2-methylidene]ethylidene]-2-chloro-1-cyclohexen-1-yl]vinyl]-3,3-dimethyl-5-sulfonic acid-3H-indol-1-ylpropylaminocarbonyl]methyldisulfide]acetoxy-6,12b-bis(acetoxy)-12-(phenylpropionic acid) Acyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methylene-1H-cyclodecano[3,4]benzo[1,2-b]oxetan-9-yl ester, [2aR-[2aα,4β,4aβ,6β,9α(αR*,βS*),11α,12α,12aα,12bα]];
[0028] Phenylpropionic acid, β-(benzoylamino)-α-[3-[2-[3-[2-[3-[1-[5-[methoxypolyethylene glycol aminocarbonyl]pentyl]-1,3-dihydro-3,3-di-methyl-2H-indol-2-methylidene]ethylidene]-2-chloro-1-cyclohexen-1-yl]vinyl]-3,3-dimethyl-5-sulfonic acid-3H-indol-1-ylpropylaminocarbonyl]ethyl]thio]methylethylidenethio]propionyloxy-6,12b-bis(acetoxy) -12-(Benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methylene-1H-cyclodecano[3,4]benzo[1,2-b]oxetan-9-yl ester, [2aR-[2aα,4β,4aβ,6β,9α(αR*,βS*),11α,12α,12aα,12bα]];
[0029] Phenylpropionic acid, β-(benzoylamino)-α-[3-[2-[3-[2-[3-[1-[5-[methoxypolyethylene glycol aminocarbonyl]pentyl]-1,3-dihydro-3,3-dimethyl-2H-indol-2-methylidene]ethylidene]-2-chloro-1-cyclohexen-1-yl]vinyl]-3,3-dimethyl-5-sulfonic acid-3H-indol-1-ylpropylaminocarbonyl]ethyl]thio]propionyloxy-6,12b-bis(acetoxy)-12- (Benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methylene-1H-cyclodecano[3,4]benzo[1,2-b]oxetan-9-yl ester, [2aR-[2aα,4β,4aβ,6β,9α(αR*,βS*),11α,12α,12aα,12bα]];
[0030] Phenylpropionic acid, β-(benzoylamino)-α-[3-[2-[3-[2-[3-[1-[5-[methoxypolyethylene glycol aminocarbonyl]pentyl]-1,3-dihydro-3,3-dimethyl-2H-indol-2-methylidene]ethylidene]-2-chloro-1-cyclohexen-1-yl]vinyl]-3,3-dimethyl-5-sulfonic acid-3H-indol-1-ylpropylaminocarbonyl]ethyl]disulfide]propionyloxy-6,12b-bis(acetoxy)-12- (Benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methylene-1H-cyclodecano[3,4]benzo[1,2-b]oxetan-9-yl ester, [2aR-[2aα,4β,4aβ,6β,9α(αR*,βS*),11α,12α,12aα,12bα]];
[0031] Phenylpropionic acid, β-(benzoylamino)-α-[4-[3-[3-[2-[3-[1-[5-[methoxypolyethylene glycol aminocarbonyl]pentyl]-1,3-dihydro-3,3-di-methyl-2H-indol-2-methylidene]ethylidene]-2-chloro-1-cyclohexen-1-yl]vinyl]-3,3-dimethyl-5-sulfonic acid-3H-indol-1-ylpropylaminocarbonyl]ethyl]disulfide]butyryloxy-6,12b-bis(acetoxy)- 12-(Benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methylene-1H-cyclodecano[3,4]benzo[1,2-b]oxetan-9-yl ester, [2aR-[2aα,4β,4aβ,6β,9α(αR*,βS*),11α,12α,12aα,12 bα]]phenylpropionic acid,β-(benzoylamino)-α-[3-[2-[3-[1-[5-[methoxypolyethylene glycol aminocarbonyl]pentyl]-1,3-dihydro-3,3-dimethyl-2H-indol-2-methylidene]ethylidene]-2-chloro-1-cyclohexen-1-yl]vinyl]-3,3-dimethyl-5-chloro-3H-indol-1-ylpropylaminocarbonyl]methyl]thio]acetoxy-6,12b-bis(acetoxy)-12-(phenyl)propionic acid ester (formyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methylene-1H-cyclodecano[3,4]benzo[1,2-b]oxetan-9-yl ester, [2aR-[2aα,4β,4aβ,6β,9α(αR*,βS*),11α,12α,12aα,12bα]];
[0032] Phenylpropionic acid, β-(benzoylamino)-α-[3-[2-[3-[2-[3-[1-[5-[methoxypolyethylene glycol aminocarbonyl]pentyl]-1,3-dihydro-3,3-dimethyl-2H-indol-2-methylidene]ethylidene]-2-chloro-1-cyclohexen-1-yl]vinyl]-3,3-dimethyl-5-chloro-3H-indol-1-ylpropylaminocarbonyl]ethyl]thiomethylethylidenethio]propanoyloxy-6,12b-bis(acetoxy)-1 2-(Benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methylene-1H-cyclodecano[3,4]benzo[1,2-b]oxetan-9-yl ester, [2aR-[2aα,4β,4aβ,6β,9α(αR*,βS*),11α,12α,12aα,12bα]];
[0033] Phenylpropionic acid, β-(benzoylamino)-α-[3-[2-[3-[2-[3-[1-[5-[methoxypolyethylene glycol aminocarbonyl]pentyl]-1,3-dihydro-3,3-dimethyl-2H-indol-2-methylidene]ethylidene]-2-chloro-1-cyclohexen-1-yl]vinyl]-3,3-dimethyl-5-chloro-3H-indol-1-ylpropylaminocarbonyl]ethyl]thio]propionyloxy-6,12b-bis(acetoxy)-12-( Benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methylene-1H-cyclodecano[3,4]benzo[1,2-b]oxetan-9-yl ester, [2aR-[2aα,4β,4aβ,6β,9α(αR*,βS*),11α,12α,12aα,12bα]];
[0034] Phenylpropionic acid, β-(benzoylamino)-α-[3-[2-[3-[2-[3-[1-[5-[methoxypolyethylene glycol aminocarbonyl]pentyl]-1,3-dihydro-3,3-dimethyl-2H-indol-2-methylidene]ethylidene]-2-chloro-1-cyclohexen-1-yl]vinyl]-3,3-dimethyl-5-chloro-3H-indol-1-ylpropylaminocarbonyl]ethyl]disulfide]propionyloxy-6,12b-bis(acetoxy)-12-( Benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methylene-1H-cyclodecano[3,4]benzo[1,2-b]oxetan-9-yl ester, [2aR-[2aα,4β,4aβ,6β,9α(αR*,βS*),11α,12α,12aα,12bα]];
[0035] Phenylpropionic acid, β-(benzoylamino)-α-[4-[3-[3-[2-[3-[1-[5-[methoxypolyethylene glycol aminocarbonyl]pentyl]-1,3-dihydro-3,3-dimethyl-2H-indol-2-methylidene]ethylidene]-2-chloro-1-cyclohexen-1-yl]vinyl]-3,3-dimethyl-5-chloro-3H-indol-1-ylpropylaminocarbonyl]ethyl]disulfide]butyryloxy-6,12b-bis(acetoxy)-12-( benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methylene-1H-cyclodecano[3,4]benzo[1,2-b]oxetan-9-yl ester, [2aR-[2aα,4β,4aβ,6β,9α(αR*,βS*),11α,12α,12aα,12bα]].
[0036] A method for preparing a PEGylated indocyanine dye-coupled paclitaxel prodrug compound,
[0037] (1) Connected with substituent R 1 The 2,3,3-trimethylindole reacted with the alkylating agent Y-(CH 2 ) m The quaternary ammonium salt 1 is prepared by COOH reaction, and the molar ratio of the substituted indole to the alkylating agent is 1:1 to 1:4;
[0038]
[0039] (2) R with a substituent 2 The 2,3,3-trimethyl-3-substituted indole was reacted with the alkylating agent Y-(CH 2 )p NH 2 ·HBr reaction to prepare quaternary ammonium salt 2, the molar ratio of substituted indole to alkylating agent is 1:1 to 1:4;
[0040]
[0041] (3) reacting the quaternary ammonium salt 2 obtained in step (2) with Boc anhydride to obtain a quaternary ammonium salt 3, wherein the molar ratio of the quaternary ammonium salt 2 to the Boc anhydride is 1:1 to 1:3;
[0042]
[0043] (4) reacting the quaternary ammonium salt 1 obtained in step (1) and the quaternary ammonium salt 3 obtained in step (3) with N-[(3-(anilinomethylene)-2-chloro-1-cyclohexene-1-yl)methylene]aniline hydrochloride 4 to obtain an indole heptamethine cyanine compound 5;
[0044]
[0045] (5) Indole heptamethine cyanine compound 5 and methoxy polyethylene glycol amine (PEG-NH 2 ) a condensation reaction is carried out under the catalysis of a condensation agent to obtain PEGylated indole heptamethine cyanine 6;
[0046]
[0047] (6) Indole heptamethine cyanine compound 6 is subjected to acidic conditions to remove the Boc protecting group to obtain indole heptamethine cyanine 7;
[0048]
[0049] (7) indole heptamethine cyanine 7 undergoes a condensation reaction with a paclitaxel derivative to obtain a compound having the general structural formula (I);
[0050]
[0051] In the step (1), Y-(CH 2 )mCOOH is a halogenated carboxylic acid containing 1 to 6 carbon atoms;
[0052] In the step (2), Y-(CH 2 ) p NH 2 HBr is the hydrobromide of a haloalkylamine having 2 to 6 carbon atoms.
[0053] The steps (1) and (2) are reacted in the presence of a solvent, the reaction time is 4 to 40 hours, and the reaction temperature is 60 to 148° C.; wherein the solvent is selected from toluene, xylene, dichlorobenzene, ethanol, methanol or acetonitrile.
[0054] In the step (4), the molar ratio of the quaternary ammonium salt 1, the quaternary ammonium salt 3, and the N-[(3-(anilinomethylene)-2-chloro-1-cyclohexene-1-yl)methylene]aniline hydrochloride 4 is 1:1:1;
[0055] The step (4) is carried out under a solvent / catalyst system, wherein the solvent / catalyst is ethanol / sodium acetate or acetic anhydride / sodium acetate, and the ratio of the catalyst to the quaternary ammonium salt 1 is 0.3:1 to 3:1.
[0056] A pharmaceutical composition comprises a PEGylated indocyanine dye coupled to paclitaxel prodrug compound represented by general formula (I) and a pharmaceutically acceptable salt, solvate and pharmaceutically acceptable carrier thereof.
[0057] The "pharmaceutically acceptable salt" described in the present invention mainly refers to an organic or inorganic group with a charge, and can be administered together with other pharmaceutical agents, such as a paired cation and paired anion in a salt. For example, cationic salts, anionic salts, and zwitterionic salts. The cations described include sodium ions, potassium ions, magnesium ions, calcium ions, zinc ions, and quaternary ammonium salts, but are not limited thereto; the anions include chloride ions, acetate ions, toluenesulfonate ions, citrates, carbonates, and bicarbonates, and the anionic salts are also not limited thereto.
[0058] An application of the compound, a PEGylated indocyanine dye coupled to paclitaxel prodrug compound represented by general formula (I) and a pharmaceutically acceptable salt thereof or the pharmaceutical composition in the preparation of anti-tumor drugs
[0059] The advantages of the present invention are:
[0060] The present invention utilizes the principle of molecular hybridization to covalently bind a PEGylated derivative methoxypolyethylene glycol amine to a near-infrared indole heptamethine cyanine dye that specifically targets tumor cell mitochondria, and then couples paclitaxel through a chemical bond that is sensitive to the high redox state of the tumor, thereby designing PEGylated cyanine dye-coupled redox-responsive paclitaxel prodrug compounds with different structures. Such compounds have the functions of both tumor targeting and tumor treatment. DETAILED DESCRIPTION
[0061] The following further describes the content of the present invention in detail through the specific implementation of the embodiment, which is an explanation of the present invention rather than a limitation. Any modifications made without departing from the spirit and principle of the present invention should be included in the protection scope of the present invention.
[0062] Example 1
[0063] Phenylpropionic acid, β-(benzoylamino)-α-[3-[2-[3-[2-[3-[1-[5-[methoxypolyethylene glycol aminocarbonyl]pentyl]-1,3-dihydro-3,3-dimethyl-2H-indol-2-methylideneethyl]-2-chloro-1-cyclohexen-1-yl]vinyl]-3,3-dimethyl-3H-indol-1-ylpropylaminocarbonyl]ethyl]thiomethylethylidenethio]propanoyloxy-6,12b-bis(acetoxy)-12-(benzoyl)propanoic acid Synthesis of 2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methylene-1H-cyclodecano[3,4]benzo[1,2-b]oxetan-9-yl ester, [2aR-[2aα,4β,4aβ,6β,9α(αR*,βS*),11α,12α,12aα,12bα]](Z-1)
[0064] (1) Synthesis of 1-(5-carboxypentyl)-2,3,3-trimethyl-3H-indolium bromide (Compound 1-1)
[0065]
[0066] 2,3,3-Trimethyl-3H-indole (10g, 62.8mmol) and 6-bromohexanoic acid (30.6g, 314.5mmol) were added to a 500mL eggplant-shaped bottle, and 350mL of acetonitrile was added. The temperature was raised to 78°C and the reaction was continued for 72h. After the reaction was completed, the acetonitrile was removed by concentration under reduced pressure, and 500mL of ethyl acetate was added and stirred to precipitate a pink solid. The solid was filtered and washed with ethyl acetate and dried in a vacuum oven to obtain 15.0g of a pink powdery solid with a yield of 67.6%. MS (ESI) m / z: 274.1[M] + .
[0067] (2) Preparation of 1-(3-aminopropyl)-2,3,3-trimethyl-3H-indolium bromide (Compound 1-2)
[0068]
[0069] 2,3,3-Trimethyl-3H-indole (10g, 62.8mmol) and 3-bromopropylamine (27g, 125mmol) were added to a 1000mL eggplant-shaped bottle, and 500mL of acetonitrile was added. The temperature was raised to 78°C and the reaction was continued for 72h. After the reaction was completed, the mixture was allowed to stand overnight until all solids were precipitated, and then filtered. The filter cake was slurried with acetonitrile for 2h, filtered, and dried under reduced pressure to obtain 15.0g of off-white solid with a yield of 80.6%. MS (ESI) m / z: 217.1[M] + .
[0070] (3) Synthesis of 1-[3-(tert-butoxycarbonylamino)propyl]-2,3,3-trimethyl-3H-indolium bromide (Compound 1-3)
[0071]
[0072] Compound 1-2 (10 g, 33.7 mmol) and Boc 2 O (22.1g, 101.3mmol) was added to 400mL chloroform solution. Compound 1-2 was insoluble. Triethylamine (13.6g, 135.1mmol) was slowly added dropwise to dissolve it completely. The temperature was raised to 60℃ and stirred for 4h. After the reaction was completed, it was washed with saturated brine for 3 times, dried over anhydrous sodium sulfate overnight, filtered and concentrated to obtain 11.0g of pink liquid, with a yield of 82.3%. MS (ESI) m / z: 317.2[M] + .
[0073] (4) Preparation of 2-[2-[3-[1-(5-carboxypentyl)-3,3-dimethylindol-2-methylideneethylidene]-2-chloro-1-cyclohexen-1-yl]vinyl]-3,3-dimethyl-1-[3-(tert-butoxycarbonylamino)propyl]-3H-indolium bromide (Compound 1-5)
[0074]
[0075] Compound 1-3 (10 g, 25.2 mmol), N-[(3-(anilinomethylene)-2-chloro-1-cyclohexene-1-yl)methylene]aniline hydrochloride (compound 4) (8.1 g, 25.2 mmol) and compound 1-1 (6.9 g, 25.2 mmol) were added to a 250 mL eggplant-shaped bottle, 100 mL of anhydrous ethanol and anhydrous sodium acetate (65.4 mg, 0.8 mmol) were added, the temperature was raised to 78 ° C and stirred for reaction, the reaction was carried out for 8 hours, the reaction solution was concentrated to dryness, and the residue was purified by column chromatography (dichloromethane: methanol = 35: 1) to obtain 1.2 g of green solid, the yield was 18.7%, MS (ESI) m / z: 726.4 [M] + .
[0076] (5) Synthesis of [2-[3-[1-[5-[[methoxypoly(oxy-1,2-ethanediyl)]aminocarbonyl]pentyl]-1,3-dihydro-3,3-dimethyl-2H-indol-2-methylideneethylidene]-2-chloro-1-cyclohexen-1-yl]vinyl]-3,3-dimethyl-1-[3-(tert-butoxycarbonylamino)propyl]-3H-indolium bromide (Compound 1-6)
[0077]
[0078] Under ice-salt bath conditions, add intermediate 1-5 (500 mg, 0.69 mmol) to dry dichloromethane. After complete dissolution, add EDCI (420 mg, 2.20 mmol) and NHS (198 mg, 1.72 mmol) dropwise, stir overnight until the raw material is completely converted into active ester, and then add methoxypolyethylene glycolamine (1.38 g, 1.38 mmol). Monitor the reaction by TLC. After the reaction is completed, concentrate under reduced pressure to remove the solvent. After purification by thin layer chromatography, 680 mg of green solid is obtained, with a yield of 51.2%. MS (FT-ICR) m / z: 976.101 [M++Na] 2+ .
[0079] (6) Synthesis of the intermediate [2-[3-[1-[5-[[methoxypoly(oxy-1,2-ethanediyl)]aminocarbonyl]pentyl]-1,3-dihydro-3,3-dimethyl-2H-indol-2-methylideneethylidene]-2-chloro-1-cyclohexen-1-yl]vinyl]-3,3-dimethyl-1-(3-aminopropyl)-3H-indolium bromide (Compound 1-7)
[0080]
[0081] Under ice bath conditions, compound 1-6 (500 mg, 0.25 mmol) was completely dissolved in 10 mL of dichloromethane, 10 mL of trifluoroacetic acid was slowly added dropwise, and the mixture was stirred and kept warm for 5 hours. After the reaction was completed, the solvent was removed by vacuum concentration, and 350 mg of green solid was obtained after column chromatography purification, with a yield of 75.7%. MS (FT-ICR) m / z: 893.044 [M + +H] 2+ .
[0082] (7) Synthesis of 5β,20-epoxy-1,2α,4,7β,10β,13α-hexahydroxytaxane-11-ene-9-one-4,10-diacetate-2-benzoate-13-[(2'R,3'S)N-benzoyl-3'-phenyl-2'-[α-(carboxyethylethylidenedisulfide)propionyloxy]isoserine ester] (Intermediate PTX-1)
[0083]
[0084] N 2Under protection, 3,3'-(propane-2,2-diylbis(sulfanediyl))dipropionic acid (252mg, 1.00mmol) was added to a 25mL eggplant-shaped bottle, dissolved with 3mL acetic anhydride, and stirred overnight at room temperature. After the reaction was completed, 18mL toluene was added to the system three times, and a white solid was obtained by vacuum distillation. The obtained solid was directly dissolved in 10mL dichloromethane, and paclitaxel (853mg, 1.00mmol) and a catalytic amount of DMAP were added, stirred overnight at room temperature, and after the reaction was completed, thin layer chromatography was purified to obtain 600mg of a white solid with a yield of 55.2% MS (ESI) m / z: 1086.1 [MH] - .
[0085] (8) Synthesis of Compound Z-1
[0086]
[0087] Under ice-salt bath conditions, compound PTX-1 (500 mg, 0.46 mmol) was dissolved in 10 mL of dry dichloromethane, and EDCI (175 mg, 0.92 mmol) and a catalytic amount of DMAP were added dropwise under stirring. After 30 minutes, compound 1-7 (821 mmol, 0.46 mmol) was added. TLC was used to monitor the reaction progress. After the reaction was completed, the solvent was removed by vacuum concentration. After purification by column chromatography, 250 mg of green solid was obtained with a yield of 20.3%. MS (FT-ICR) m / z: 1439.267 [M + +Na] 2+ ; 1 H-NMR (600 MHz, DMSO-d 6)δ9.27(t,J=8.6Hz,1H),8.28(d,J=14.0Hz,1H),8.23(d,J=13.8Hz,1H),8.16(d,J=5.8Hz,1H),7.99–7.95(m,2H),7.87(s,1H),7.84(dd,J=12.1,6.1Hz,2H),7.73(t,J=7.3Hz,1H),7.68–7.59(m,4H),7.53(t,J=7.3Hz,1H),7.47(dd,J=8.0,2.3Hz,3H),7.44(dd,J=5.9,2.8Hz,6H),7.43–7.39(m,2H),7.32–7.25(m,2H),7.17(tt,J=5.7,3.0Hz,1H),6.35(d,J=14.2Hz,1H),6.29(q,J=4.7Hz,2H),5.82(d,J=9.0Hz,1H),5.54(t,J=8.9Hz,1H),5.39(dd,J=14.7,8.1Hz,2H),4.90(dq,J=9.6,3.8,2.5Hz,2H),4.62(s,1H),4.21(d,J=7.7Hz,4H),4.10(dd,J=11.5,6.1Hz,1H),4.00(q,J=8.3Hz,2H),3.61(d,J=4.8Hz,1H),3.57(d,J=7.2Hz,1H),3.49(dq,J=6.7,2.3Hz,128H),3.42(dd,J=5.9,3.6Hz,3H),3.23(s,3H),3.21–3.17(m,2H),3.15(d,J=5.8Hz,2H),2.75(d,J=6.7Hz,2H),2.73–2.70(m,4H),2.70(s,3H),2.35(t,J=7.5Hz,2H),2.22(s,3H),2.09(s,3H),2.06(t,J=7.3Hz,2H),1.90(d,J=6.1Hz,1H),1.89–1.83(m,3H),1.78(s,4H),1.76–1.69(m,3H),1.66(d,J=3.7Hz,11H),1.56–1.52(m,3H),1.49(s,4H),1.44(s,6H),1.35(p,J=7.7Hz,2H),1.23(d,J=5.2Hz,1H),1.02(s,3H),0.99(s,3H); 13 C-NMR(151MHz,DMSO-d 6)δ202.39,172.76,172.00,171.79,170.90,170.53,169.68,169.16,168.80,166.40, 165.25,148.13,143.50,142.69,142.07,142.01,141.21,140.99,139.38,137.28,134 .22,133.54,133.42,131.50,129.96,129.60,128.73,128.60,128.31,128.26,127.69,127.50,126.36,126.15,125.44,125.04,122.56,111.77,111.24,102.12,101.14,83 .62,80.26,76.73,75.30,74.74,74.71,74.50,71.30,70.85,70.44,69.80,69.60,69.17,58.07,57.42,55.83,54.07,49.17,48.89,46.09,43.84,42.95,41.73,38.43,36. 52,36.12,35.23,34.99,34.38,34.03,30.51,30.47,27.51,27.46,27.09,26.85,26.34,25.88,25.86,25.74,25.59,24.87,24.65,22.60,21.38,20.67,20.42,13.93,9.77.
[0088] Example 2
[0089] Phenylpropionic acid, β-(benzoylamino)-α-[3-[2-[3-[2-[3-[1-[5-[methoxypolyethylene glycol aminocarbonyl]pentyl]-1,3-dihydro-3,3-dimethyl-2H-indol-2-methylideneethyl]-2-chloro-1-cyclohexen-1-yl]vinyl]-3,3-dimethyl-3H-indol-1-ylpropylaminocarbonyl]ethyl]thio]propionyloxy-6,12b-bis(acetoxy)-12-(benzoyloxy) Synthesis of 2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methylene-1H-cyclodecano[3,4]benzo[1,2-b]oxetan-9-yl ester, [2aR-[2aα,4β,4aβ,6β,9α(αR*,βS*),11α,12α,12aα,12bα]](Z-2)
[0090] (1) Synthesis of 5β,20-epoxy-1,2α,4,7β,10β,13α-hexahydroxytaxane-11-ene-9-one-4,10-diacetate-2-benzoate-13-[(2'R,3'S)N-benzoyl-3'-phenyl-2'-[α-(carboxyethylthio)propionyloxy]isoserine ester] (Compound PTX-2)
[0091]
[0092] The same synthesis method as compound PTX-1 was used, with 3,3'-thiodipropionic acid (178.0 mg, 1.00 mmol) and paclitaxel (853 mg, 1.00 mmol) as raw materials, and 600 mg of white solid was obtained with a yield of 59.2%. MS (ESI) m / z: 1012.4 [MH] - .
[0093] (2) Synthesis of Compound Z-2
[0094]
[0095] The same synthesis method as that of compound Z-1 in Example 1 was used to react compound 1-7 with compound PTX-2 to obtain Z-2 as a green solid, with an amount of 260 mg and a yield of 20.3%. MS (FT-ICR) m / z: 957.1574 [M + +H+Na] 3+ ; 1 H-NMR (600 MHz, DMSO-d 6)δ9.31(d,J=8.6Hz,1H),8.30–8.22(m,3H),7.99–7.96(m,1H),7.88–7.82(m,3H),7.73(t,J=7.4Hz,1H),7.64(ddd,J=22.6,12.4,7.2Hz,4H),7.56–7.39(m,10H),7.33–7.24(m,2H),7.20–7.16(m,1H),6.38–6.26(m,3H),5.81(t,J=9.0Hz,1H),5.55(t,J=8.7Hz,1H),5.40(dd,J=10.8,8.1Hz,2H),4.92–4.88(m,1H),4.63(s,1H),4.22(dq,J=9.3,5.3,4.6Hz,4H),4.13–4.07(m,1H),4.00(q,J=8.3Hz,1H),3.61(d,J=4.9Hz,1H),3.59(s,1H),3.57(d,J=7.1Hz,1H),3.53–3.46(m,128H),3.42(dd,J=5.9,3.7Hz,3H),3.36(dt,J=5.9,2.9Hz,3H),3.24–3.13(m,9H),2.92–2.81(m,6H),2.71(td,J=6.8,2.9Hz,5H),2.47(s,1H),2.23(s,2H),2.09–2.05(m,4H),1.91–1.70(m,11H),1.67(d,J=2.0Hz,8H),1.66(s,4H),1.55(td,J=7.5,4.0Hz,2H),1.49(s,2H),1.36(dp,J=9.2,3.5,3.0Hz,2H),1.23(s,1H),1.07–0.82(m,6H); 13 C-NMR(151MHz,DMSO-d 6)δ202.63,173.00,172.23,172.05,171.91,170.90,170.43,169.93,169.41,169.05,166.73 ,165.51,148.37,143.74,142.95,142.33,142.28,141.48,141.25,139.65,137.53,134.49, 133.79,133.68,131.76,130.22,129.86,128.98,128.87,128.58,128.50,127.95,127.76,126.62,126.40,125.69,125.29,122.85,122.81,112.03,111.53,102.38,101.40,83.88,80.5 2,76.98,75.56,75.04,75.00,74.76,71.56,71.13,70.70,70.06,69.86,69.43,58.32,57.67,54.30,51.81,49.42,49.16,46.35,44.10,43.21,42.01,38.68,36.78,36.43,36.38,35.25 ,35.22,35.19,34.63,33.99,33.96,33.56,33.27,32.93,32.46,27.77,27.72,27.33,27.11,26.61,26.15,26.12,26.00,25.13,22.86,22.37,21.63,20.93,20.69,14.22,14.19,10.03.
[0096] Example 3
[0097] Phenylpropionic acid, β-(benzoylamino)-α-[3-[2-[3-[2-[3-[1-[5-[methoxypolyethylene glycol aminocarbonyl]pentyl]-1,3-dihydro-3,3-di-methyl-2H-indol-2-methylidene]ethylidene]-2-chloro-1-cyclohexen-1-yl]vinyl]-3,3-dimethyl-3H-indol-1-ylpropylaminocarbonyl]ethyl]disulfide]propionyloxy-6,12b-bis(acetoxy)-12-(benzoyloxy) Synthesis of -2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methylene-1H-cyclodecano[3,4]benzo[1,2-b]oxetan-9-yl ester, [2aR-[2aα,4β,4aβ,6β,9α(αR*,βS*),11α,12α,12aα,12bα]](Z-3):
[0098] (1) Preparation of 5β,20-epoxy-1,2α,4,7β,10β,13α-hexahydroxytaxane-11-ene-9-one-4,10-diacetate-2-benzoate-13-[(2'R,3'S)N-benzoyl-3'-phenyl-2'-[α-(carboxyethyldisulfide)propionyloxy]isoserine ester] (Compound PTX-3)
[0099]
[0100] The same synthesis method as compound PTX-1 was used to react 3,3'-dithiodipropionic acid (210 mg, 1.00 mmol) and paclitaxel (853 mg, 1.00 mmol) as raw materials to obtain 620 mg of white solid with a yield of 60.3%. MS (ESI) m / z: 1045.3 [MH] - .
[0101] (3) Synthesis of Compound Z-3
[0102]
[0103] The same synthesis method as that of compound Z-1 in Example 1 was used to react compound 1-7 with compound PTX-3 to obtain compound Z-3 as a green solid, with an amount of 260 mg and a yield of 20.4%. MS (FT-ICR) m / z: 982.155 [M+H+H] 3+ ; 1 H-NMR (600 MHz, DMSO-d 6)δ9.3(d,J=8.5Hz,1H),8.31–8.20(m,3H),8.00–7.95(m,2H),7.90–7.82(m,3H),7.73(t,J=7.4Hz,1H),7.60(ddd,J=22.5,12.3,7.2Hz,4H),7.54(t,J=7.3Hz,1H),7.50–7.40(m,9H),7.33–7.24(m,2H),7.18(tq,J=6.3,3.2,2.3Hz,1H),6.39–6.25(m,3H),5.82(t,J=9.0Hz,1H),5.55(t,J=8.7Hz,1H),5.40(dd,J=10.8,8.1Hz,2H),4.93–4.88(m,1H),4.63(s,1H),4.27–4.17(m,4H),4.14–4.06(m,1H),4.00(q,J=8.3Hz,2H),3.60(s,1H),3.58(s,1H),3.50(d,J=2.2Hz,124H),3.42(dd,J=5.8,3.7Hz,2H),3.36(dd,J=6.0,3.2Hz,2H),3.24(s,6H),3.17–3.14(m,2H),2.94–2.80(m,6H),2.71(td,J=6.9,3.0Hz,5H),2.35–2.27(m,1H),2.23(s,2H),2.11–2.04(m,5H),1.88(ddt,J=17.4,11.1,5.8Hz,4H),1.78(s,3H),1.76–1.70(m,3H),1.67(t,J=2.5Hz,13H),1.58–1.47(m,6H),1.36(td,J=7.7,3.8Hz,2H),1.23(s,2H),1.01(d,J=19.4Hz,4H); 13 C-NMR(151MHz,DMSO-d 6)δ202.36,172.73,171.95,171.77,171.63,170.62,170.16,169.66,169.14,168.77,166.45,165.23 ,148.09,143.46,142.67,142.05,142.00,141.20,140.97,139.38,137.25,134.21,133.51,133.41, 131.48,129.95,129.58,128.70,128.60,128.30,128.23,127.67,127.49,126.34,126.12,125.41,125.01,122.57,122.53,111.76,111.25,102.11,101.12,83.60,80.24,76.70,75.28,74.76,74.72,7 4.48,71.28,70.85,70.43,69.78,69.58,69.15,58.05,57.39,54.02,51.53,49.15,48.88,46.07,43.82,42.94,41.73,39.94,39.80,39.66,39.52,39.38,39.24,39.10,38.41,36.51,36.15,36.10,34. 97,34.94,34.91,34.35,33.71,33.68,33.28,32.99,32.66,32.19,31.29,29.01,27.49,27.44,27.05,26.84,26.33,25.87,25.84,25.72,24.85,22.58,22.09,21.35,20.65,20.41,13.94,13.91,9.76..
[0104] Example 4
[0105] Phenylpropionic acid, β-(benzoylamino)-α-[4-[3-[3-[2-[3-[1-[5-[methoxypolyethylene glycol aminocarbonyl]pentyl]-1,3-dihydro-3,3-dimethyl-2H-indol-2-methylidene]ethylidene]-2-chloro-1-cyclohexen-1-yl]vinyl]-3,3-dimethyl-3H-indol-1-ylpropylaminocarbonyl]ethyl]disulfide]butyryloxy-6,12b-bis(acetoxy)-12-(benzoyloxy) Synthesis of -2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methylene-1H-cyclodecano[3,4]benzo[1,2-b]oxetan-9-yl ester, [2aR-[2aα,4β,4aβ,6β,9α(αR*,βS*),11α,12α,12aα,12bα]](Z-4):
[0106] (1) Synthesis of 5β,20-epoxy-1,2α,4,7β,10β,13α-hexahydroxytaxane-11-ene-9-one-4,10-diacetate-2-benzoate-13-[(2'R,3'S)N-benzoyl-3'-phenyl-2'-[α-(carboxypropylthio)butyryloxy]isoserine ester] (compound PTX-4)
[0107]
[0108] The same synthesis method as compound PTX-1 was used to react 4,4'-dithiodibutyric acid (238 mg, 1.00 mmol) and paclitaxel (853 mg, 1.00 mmol) as raw materials to obtain 650 mg of white solid with a yield of 60.5%. MS (ESI) m / z: 1072.4 [MH] - .
[0109] (2) Synthesis of Compound Z-4
[0110]
[0111] The same synthesis method as that of compound Z-1 in Example 1 was used to react compound 1-7 with compound PTX-4 to obtain compound Z-4 as a green solid with an amount of 250 mg and a yield of 19.8%. 1 H-NMR (600 MHz, DMSO-d 6)δ9.23(d,J=8.4Hz,1H),8.26(d,J=13.8Hz,2H),8.04(t,J=5.7Hz,1H),7.99–7.96(m,2H),7.87–7.80(m,4H),7.74(t,J=7.3Hz,1H),7.69–7.62(m,4H),7.55(t,J=7.3Hz,1H),7.50–7.41(m,8H),7.39(d,J=8.4Hz,1H),7.29(ddd,J=8.0,5.4,2.8Hz,1H),7.18(ddt,J=6.4,4.7,2.2Hz,1H),6.35–6.28(m,3H),5.81(t,J=9.1Hz,1H),5.76(s,1H),5.53(t,J=8.8Hz,1H),5.41(d,J=7.2Hz,1H),5.36(d,J=9.1Hz,1H),4.90(dd,J=8.4,4.3Hz,2H),4.62(s,1H),4.21(q,J=7.3,6.8Hz,3H),4.10(dt,J=11.2,7.0Hz,1H),4.01(q,J=8.3Hz,2H),3.59(dd,J=26.0,6.1Hz,2H),3.52–3.47(m,88H),3.42(dd,J=5.9,3.7Hz,2H),3.36(t,J=6.0Hz,2H),3.24(s,3H),3.18(dq,J=17.2,6.2Hz,4H),2.73–2.63(m,8H),2.24–2.17(m,5H),2.08(d,J=21.4Hz,5H),1.92–1.80(m,9H),1.78(s,4H),1.72(t,J=7.6Hz,2H),1.67(s,12H),1.55(q,J=7.4Hz,2H),1.49(s,4H),1.34(dd,J=14.9,7.4Hz,2H),1.23(s,1H),1.01(d,J=19.2Hz,6H).; 13C-NMR(151MHz,DMSO-d)δ202.20,172.43,172.04,171.82,171.77,171.38,169.52,169. 17,168.63,166.23,165.08,148.02,145.71,142.91,141.88,141.85,140.95,140.35,13 9.17,137.16,134.06,133.38,133.30,131.36,129.80,129.44,128.59,128.55,128.45,128.19,128.09,127.47,127.29,126.28,126.15,125.05,122.44,119.79,111.19,110. 57,101.82,101.36,83.46,80.11,76.55,75.13,74.56,74.44,74.34,71.14,70.74,70.27,69.64,69.44,69.01,57.90,57.25,54.78,53.90,48.88,45.92,43.70,42.79,41.67, 38.28,37.00,36.36,36.03,35.93,34.85,34.22,33.58,31.44,27.32,27.26,27.00,26.61,26.18,25.69,25.59,24.72,24.42,23.71,22.42,21.22,20.51,20.25,13.72,9.62.
[0112] Example 5
[0113] Phenylpropionic acid, β-(benzoylamino)-α-[3-[2-[3-[1-[5-[methoxypolyethylene glycol aminocarbonyl]pentyl]-1,3-dihydro-3,3-di-methyl-2H-indol-2-methylidene]ethylidene]-2-chloro-1-cyclohexen-1-yl]vinyl]-3,3-dimethyl-5-sulfonic acid-3H-indol-1-ylpropylaminocarbonyl]methylthio]acetoxy-6,12b-bis(acetoxy)-12-(benzoyloxy)- Synthesis of 2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methylene-1H-cyclodecano[3,4]benzo[1,2-b]oxetan-9-yl ester, [2aR-[2aα,4β,4aβ,6β,9α(αR*,βS*),11α,12α,12aα,12bα]](Z-5):
[0114] (1) Preparation of 5β,20-epoxy-1,2α,4,7β,10β,13α-hexahydroxytaxane-11-ene-9-one-4,10-diacetate-2-benzoate-13-[(2'R,3'S)N-benzoyl-3'-phenyl-2'-[α-(carboxymethylthio)acetoxy]isoserine ester] (PTX-5)
[0115] The same synthesis method as compound PTX-1 was used, with 2,2'-thiodiacetic acid (150 mg, 1.00 mmol) and paclitaxel (853 mg, 1.00 mmol) as raw materials, and the crude product was purified by thin layer chromatography to obtain 600 mg of white solid, with a yield of 60.9%. MS (ESI) m / z: 984.2 [MH] - .
[0116]
[0117] (3) Preparation of [2-[3-[1-[5-[[methoxypoly(oxy-1,2-ethanediyl)]aminocarbonyl]pentyl]-1,3-dihydro-3,3-dimethyl-5-sulfonic acid-2H-indol-2-methylideneethylidene]-2-chloro-1-cyclohexen-1-yl]vinyl]-3,3-dimethyl-1-(3-aminopropyl)-3H-indolium bromide (Compound 1-8)
[0118]
[0119] The same synthesis method as compound 1-7 in Example 1 was used to prepare compound 1-8 with 4-sulfonic acid phenylhydrazine as the starting material. The yield was 70.0%. MS (FT-ICR) m / z: 866.965 [M+H+H] 2+ .
[0120] (4) Synthesis of Compound Z-5
[0121]
[0122] The same synthesis method as that of compound Z-1 in Example 1 was used to react compound 1-8 with compound PTX-5 to obtain compound Z-5 as a green solid, with an amount of 270 mg and a yield of 19.8%. MS (FT-ICR) m / z: 981.7754 [M+H+H+Na] 3+ ; 1 H-NMR (600 MHz, DMSO-d 6)δ9.25(d,J=8.3Hz,1H),8.26(dd,J=13.9,4.7Hz,2H),8.21(t,J=5.6Hz,1H),7.98–7.95(m,2H),7.85–7.83(m,2H),7.82–7.79(m,2H),7.75–7.71(m,1H),7.66(dd,J=8.3,6.8Hz,3H),7.63(d,J=7.3Hz,1H),7.51(td,J=7.0,1.4Hz,1H),7.47–7.40(m,8H),7.39(d,J=8.4Hz,1H),7.28(ddd,J=7.9,5.6,2.7Hz,1H),7.16(tt,J=6.5,2.1Hz,1H),6.35–6.27(m,3H),5.80(t,J=9.1Hz,1H),5.52(t,J=8.8Hz,1H),5.39(dd,J=11.2,8.2Hz,2H),4.89(d,J=7.1Hz,2H),4.61(s,1H),4.21(d,J=9.4Hz,4H),4.09(dt,J=10.6,7.1Hz,1H),4.03–3.96(m,2H),3.64–3.59(m,2H),3.58–3.55(m,1H),3.52–3.46(m,84H),3.42(dd,J=5.9,3.7Hz,2H),3.36(t,J=6.0Hz,2H),3.24(d,J=12.3Hz,5H),3.20(q,J=7.5,6.6Hz,2H),3.15(q,J=5.9Hz,2H),2.69(t,J=6.0Hz,4H),2.23(s,3H),2.09(s,2H),2.05(t,J=7.3Hz,2H),1.86(dt,J=21.9,6.3Hz,4H),1.80–1.75(m,4H),1.72(t,J=7.5Hz,2H),1.67(s,12H),1.53(q,J=7.5Hz,2H),1.49(s,3H),1.34(td,J=8.2,5.3Hz,2H),1.23(d,J=5.1Hz,1H),1.00(d,J=20.4Hz,6H).; 13 C-NMR(151MHz,DMSO-d 6)δ202.33,172.68,172.06,171.94,169.66,169.42,169.07,168.76,168.62,166. 36,165.23,148.17,145.91,143.15,142.98,142.01,141.97,141.05,140.51,139 .27,137.25,134.15,133.52,133.47,131.47,129.93,129.59,128.74,128.69,128.62,128.28,127.59,127.44,126.47,126.33,125.14,122.58,119.93,111.28,1 10.76,102.05,101.38,83.59,80.24,76.68,75.27,75.12,74.69,74.48,71.28,70.96,70.42,69.78,69.58,69.15,58.04,57.40,54.11,49.06,48.97,46.05,43.8 7,42.92,41.67,38.41,36.49,36.37,34.99,34.33,34.30,32.55,27.48,27.39,27.03,26.76,26.31,25.83,25.73,24.85,22.60,21.34,20.65,20.36,13.86,9.75.
[0123] Example 6
[0124] Phenylpropionic acid, β-(benzoylamino)-α-[3-[2-[3-[1-[5-[methoxypolyethylene glycol aminocarbonyl]pentyl]-1,3-dihydro-3,3-di-methyl-2H-indol-2-methylidene]ethylidene]-2-chloro-1-cyclohexen-1-yl]vinyl]-3,3-dimethyl-5-sulfonic acid-3H-indol-1-ylpropylaminocarbonyl]methyldisulfide]acetoxy-6,12b-bis(acetoxy)-12-(benzoyloxy) Synthesis of -2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methylene-1H-cyclodecano[3,4]benzo[1,2-b]oxetan-9-yl ester, [2aR-[2aα,4β,4aβ,6β,9α(αR*,βS*),11α,12α,12aα,12bα]](Z-6):
[0125] (1) (1) Preparation of 5β,20-epoxy-1,2α,4,7β,10β,13α-hexahydroxytaxane-11-ene-9-one-4,10-diacetate-2-benzoate-13-[(2'R,3'S)N-benzoyl-3'-phenyl-2'-[α-(carboxymethyldisulfide)acetoxy]isoserine ester] (compound PTX-6)
[0126]
[0127] The same synthesis method as compound PTX-1 was used to react 2,2'-dithiodiacetic acid (182 mg, 1.00 mmol) and paclitaxel (853 mg, 1.00 mmol) as raw materials to obtain 620 mg of white solid with a yield of 60.3%. MS (ESI) m / z: 1016.3 [MH] - .
[0128] (2) Preparation of Compound Z-6
[0129]
[0130] The same synthesis method as that of compound Z-1 in Example 1 was used to react compound 1-8 with compound PTX-6 to obtain compound Z-6 as a green solid, with an amount of 280 mg and a yield of 20.7%. MS (FT-ICR) m / z: 963.085 [M+H+H+Na] 3+ ; 1 H-NMR (600 MHz, DMSO-d 6)δ9.29(d,J=8.2Hz,1H),8.35(dd,J=10.7,5.5Hz,1H),8.26(d,J=14.2Hz,2H),7.99–7.95(m,2H),7.88–7.79(m,4H),7.75–7.71(m,1H),7.69–7.61(m,4H),7.53(t,J=7.3Hz,1H),7.48–7.36(m,9H),7.28(q,J=7.0Hz,1H),7.16(tt,J=6.0,2.9Hz,1H),6.35–6.27(m,3H),5.79(t,J=8.9Hz,1H),5.50(t,J=8.9Hz,1H),5.41(dd,J=16.1,8.3Hz,2H),4.90(dd,J=8.5,3.8Hz,2H),4.60(s,1H),4.26–4.17(m,4H),4.10(td,J=7.3,3.7Hz,1H),4.03–3.97(m,2H),3.86(d,J=4.9Hz,2H),3.63(s,1H),3.56(d,J=7.2Hz,1H),3.51–3.47(m,92H),3.42(dd,J=5.9,3.7Hz,2H),3.37–3.34(m,2H),3.23(s,5H),3.16(ddt,J=8.4,6.0,2.4Hz,3H),2.70(d,J=7.8Hz,4H),2.34–2.28(m,1H),2.22(s,2H),2.07(d,J=19.6Hz,5H),1.90(q,J=7.5,5.2Hz,2H),1.85(q,J=6.4Hz,2H),1.77(t,J=3.1Hz,3H),1.72(d,J=8.8Hz,3H),1.67(d,J=3.3Hz,12H),1.56–1.52(m,2H),1.49(s,3H),1.34(dq,J=8.8,4.7Hz,2H),1.25–1.21(m,1H),0.100(d,J=21.0Hz,6H); 13 C-NMR(151MHz,DMSO-d 6)δ202.35,172.57,172.18,171.97,169.68,169.09,168.81,168.77,167.82,1 66.33,165.25,148.17,145.81,143.07,142.02,141.99,141.08,140.50,139. 30,137.24,134.23,133.54,133.45,131.48,129.93,129.59,128.73,128.70,128.30,127.69,127.48,126.47,126.39,126.29,125.19,122.58,119.92,111 .36,110.72,101.98,101.51,83.60,80.22,76.67,75.28,75.22,74.71,74.48,71.28,70.92,70.42,69.78,69.58,69.16,58.05,57.40,54.23,52.21,49.01 ,46.05,43.85,42.92,41.77,38.42,36.50,35.00,34.31,27.48,27.41,26.97,26.76,26.33,25.84,25.74,24.86,22.65,21.35,20.65,20.38,13.90,9.76.
[0131] Example 7
[0132] Phenylpropionic acid, β-(benzoylamino)-α-[3-[2-[3-[2-[3-[1-[5-[methoxypolyethylene glycol aminocarbonyl]pentyl]-1,3-dihydro-3,3-dimethyl-2H-indol-2-methylidene]ethylidene]-2-chloro-1-cyclohexen-1-yl]vinyl]-3,3-dimethyl-5-sulfonic acid-3H-indol-1-ylpropylaminocarbonyl]ethyl]thio]methylethylidenethio]propionyloxy-6,12b-bis(acetoxy)-12- Synthesis of (benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methylene-1H-cyclodecano[3,4]benzo[1,2-b]oxetane-9-yl ester, [2aR-[2aα,4β,4aβ,6β,9α(αR*,βS*),11α,12α,12aα,12bα]](Z-7):
[0133]
[0134] The same synthesis method as that of compound Z-1 in Example 1 was used to react compound 1-8 with compound PTX-1 to obtain Z-7 as a green solid, with an amount of 290 mg and a yield of 21.4%. MS (FT-ICR) m / z: 986.443 [M+H+H+Na] 3+ ; 1 H-NMR (600 MHz, DMSO-d 6 )δ9.22(d,J=8.5Hz,1H),8.26(d,J=13.7Hz,2H),8.10(t,J=5.6Hz,1H),7.99–7.96(m,2H),7.87–7.84(m,2H),7.84–7.8 0(m,2H),7.75–7.71(m,1H),7.69–7.61(m,4H),7.55–7.52(m,1H),7.48–7.40(m,8H),7.38(d,J=8.4Hz,1H),7.28(td,J =7.1,1.5Hz,1H),7.18(hept,J=3.9Hz,1H),6.35–6.27(m,3H),5.84–5.79(m,1H),5.54(t,J=8.8Hz,1H),5.39(dd,J=23 .1,8.1Hz,2H),4.92–4.88(m,2H),4.62(s,1H),4.21(dt,J=14.8,7.6Hz,4H),4.10(dt,J=10.8,7.1Hz,1H),4.00(q,J=8 .3Hz,2H),3.59(dd,J=26.4,5.9Hz,2H),3.53–3.45(m,84H),3.42(dd,J=5.9,3.7Hz,2H),3.36(t,J=6.0Hz,2H),3.23(s ,3H),3.22–3.14(m,4H),2.76(t,J=7.3Hz,2H),2.72(d,J=7.6Hz,3H),2.70(s,4H),2.34(t,J=7.4Hz,2H),2.22(s,3H), 2.07(d,J=19.9Hz,5H),1.91–1.83(m,4H),1.81–1.77(m,4H),1.72(t,J=7.4Hz,2H),1.68–1.65(m,12H),1.56–1.51(m, 2H),1.49(s,3H),1.44(d,J=1.7Hz,6H),1.34(td,J=8.9,8.5,4.9Hz,2H),1.23(d,J=4.4Hz,1H),1.01(d,J=20.2Hz,6H); 13 C-NMR (151 MHz, DMSO-d 6)δ202.31,172.54,172.13,171.92,170.85,170.44,169.61,169.07,168.73,166.34,165.1 8,148.13,145.81,143.02,141.96,141.05,140.45,139.31,137.21,134.17,133.48,133.38 ,131.44,129.91,129.54,128.68,128.55,128.26,128.20,127.62,127.43,126.40,126.29,125.15,122.54,119.89,111.32,110.68,101.92,101.49,83.56,80.21,76.67,75.24,74.68 ,74.64,74.45,71.24,70.79,70.39,69.75,69.54,69.12,58.01,57.36,55.77,53.98,48.98,48.96,46.04,43.80,42.90,41.77,39.90,39.77,39.62,39.49,39.35,39.21,39.07,38.38 ,36.47,36.06,35.17,34.96,34.33,33.97,30.46,30.42,28.99,27.43,27.37,27.10,26.72,26.29,25.82,25.78,25.69,25.52,24.82,24.60,22.54,21.32,20.62,20.35,13.87,9.72.
[0135] Example 8
[0136] Phenylpropionic acid, β-(benzoylamino)-α-[3-[2-[3-[2-[3-[1-[5-[methoxypolyethylene glycol aminocarbonyl]pentyl]-1,3-dihydro-3,3-dimethyl-2H-indol-2-methylidene]ethylidene]-2-chloro-1-cyclohexen-1-yl]vinyl]-3,3-dimethyl-5-sulfonic acid-3H-indol-1-ylpropylaminocarbonyl]ethyl]thio]propionyloxy-6,12b-bis(acetyloxy)-12-(benzoyl)propanoic acid Synthesis of 2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methylene-1H-cyclodecano[3,4]benzo[1,2-b]oxetane-9-yl ester, [2aR-[2aα,4β,4aβ,6β,9α(αR*,βS*),11α,12α,12aα,12bα]] (Z-8):
[0137]
[0138] The same synthesis method as that of compound Z-1 in Example 1 was used to react compound 1-8 with compound PTX-2 to obtain Z-8 as a green solid, with an amount of 250 mg and a yield of 18.4%. MS (FT-ICR) m / z: 976.441 [M+H+H+Na] 3+ ; 1 H-NMR (600 MHz, DMSO-d 6)δ9.23(d,J=8.6Hz,1H),8.26(d,J=13.8Hz,2H),8.09(t,J=5.6Hz,1H),7.99–7.96(m,2H),7.86–7.80(m,4H),7.73(t,J=7.4Hz,1H),7.68–7.61(m,4H),7.54(t,J=7.3Hz,1H),7.49–7.37(m,9H),7.28(t,J=6.8Hz,1H),7.18(p,J=4.3Hz,1H),6.36–6.27(m,3H),5.82(t,J=9.0Hz,1H),5.55(t,J=8.8Hz,1H),5.41(d,J=7.2Hz,1H),5.36(d,J=8.9Hz,1H),4.92–4.89(m,2H),4.63(s,1H),4.21(dt,J=14.4,7.4Hz,4H),4.09(q,J=8.5,6.3Hz,1H),4.01(q,J=8.3Hz,2H),3.63–3.55(m,2H),3.50(dd,J=6.9,3.7Hz,88H),3.42(dd,J=5.9,3.6Hz,2H),3.36(t,J=6.0Hz,3H),3.23(s,3H),3.20(d,J=6.2Hz,2H),3.16(t,J=5.6Hz,3H),2.70(d,J=10.3Hz,7H),2.65(t,J=7.2Hz,2H),2.33(t,J=7.4Hz,2H),2.23(s,2H),2.09(s,3H),2.06(t,J=7.3Hz,2H),1.91–1.83(m,4H),1.78(s,4H),1.72(t,J=7.6Hz,2H),1.67(s,11H),1.53(q,J=7.3Hz,3H),1.49(s,3H),1.35(q,J=7.8Hz,2H),1.23(s,2H),1.00(d,J=20.6Hz,6H); 13 C-NMR(151MHz,DMSO-d 6)δ202.35,172.58,172.18,171.96,170.96,170.52,169.65,169.11,168.78,166.4 5,165.23,148.15,145.84,143.05,142.00,141.08,140.49,139.37,137.26,134.2 3,133.51,133.41,131.49,129.94,129.58,128.71,128.32,128.24,127.64,127.45,126.44,126.32,125.19,122.57,119.93,111.37,110.71,101.96,101.52,83.60, 80.26,76.70,75.28,74.72,74.67,74.49,71.28,70.83,70.44,69.78,69.58,69.15,58.05,57.41,53.99,49.03,49.00,48.60,46.07,43.84,42.94,41.80,38.42,36 .50,36.10,35.66,34.99,34.37,33.98,29.02,27.47,27.41,27.13,26.87,26.75,26.33,25.94,25.84,25.73,24.86,22.57,22.08,21.35,20.66,20.37,13.90,9.76.
[0139] Example 9
[0140] Phenylpropionic acid, β-(benzoylamino)-α-[3-[2-[3-[2-[3-[1-[5-[methoxypolyethylene glycol aminocarbonyl]pentyl]-1,3-dihydro-3,3-dimethyl-2H-indol-2-methylidene]ethylidene]-2-chloro-1-cyclohexen-1-yl]vinyl]-3,3-dimethyl-5-sulfonic acid-3H-indol-1-ylpropylaminocarbonyl]ethyl]disulfide]propionyloxy-6,12b-bis(acetyloxy)-12-(benzoyl)propanoic acid Synthesis of (2aR-[2aα,4β,4aβ,6β,9α(αR*,βS*),11α,12α,12aα,12bα)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methylene-1H-cyclodecano[3,4]benzo[1,2-b]oxetan-9-yl ester, [2aR-[2aα,4β,4aβ,6β,9α(αR*,βS*),11α,12α,12aα,12bα]](Z-9):
[0141]
[0142] The same synthesis method as that of compound Z-1 in Example 1 was used to react compound 1-8 with compound PTX-3 to obtain Z-9 as a green solid, with an amount of 260 mg and a yield of 19.1%. MS (FT-ICR) m / z: 987.103 [M+H+H+Na] 3+ ; 1 H-NMR (600 MHz, DMSO-d 6)δ9.22(d,J=8.6Hz,1H),8.26(dd,J=13.9,4.4Hz,2H),8.14(t,J=5.6Hz,1H),7.99–7.96(m,2H),7.86–7.79(m,4H),7.72(d,J=7.4Hz,1H),7.68–7.61(m,4H),7.53(d,J=7.5Hz,1H),7.47(t,J=7.6Hz,2H),7.45–7.42(m,6H),7.39(d,J=8.4Hz,1H),7.28(td,J=6.9,6.2,2.3Hz,1H),7.19(q,J=4.3Hz,1H),6.35–6.28(m,3H),5.82(t,J=9.0Hz,1H),5.56(t,J=8.7Hz,1H),5.41(d,J=7.2Hz,1H),5.36(d,J=8.9Hz,1H),4.92–4.88(m,2H),4.63(s,1H),4.21(q,J=8.4Hz,4H),4.10(dt,J=11.0,7.0Hz,1H),4.01(q,J=8.3Hz,2H),3.59(dd,J=25.3,6.1Hz,2H),3.51–3.47(m,104H),3.42(dd,J=5.9,3.6Hz,2H),3.36(t,J=6.0Hz,2H),3.23(s,5H),3.16(q,J=5.8Hz,2H),2.90(t,J=6.9Hz,2H),2.84(dt,J=17.7,6.4Hz,4H),2.70(t,J=6.5Hz,4H),2.46(t,J=7.1Hz,2H),2.31(tt,J=8.1,4.9Hz,1H),2.23(s,3H),2.09(s,3H),2.06(t,J=7.3Hz,2H),1.91–1.83(m,4H),1.78(s,4H),1.72(t,J=7.5Hz,2H),1.67(s,5H),1.67(s,5H),1.54(q,J=6.9,6.4Hz,3H),1.49(s,3H),1.35(q,J=7.9Hz,2H),1.23(s,1H),1.01(d,J=20.0Hz,6H); 13 C-NMR(151MHz,DMSO-d 6)δ202.35,172.63,172.13,171.95,170.64,170.14,169.64,169.07,168.78,166.49, 165.23,148.16,145.87,143.11,143.01,141.99,141.07,140.50,139.34,137.21,13 4.23,133.51,133.43,131.50,129.95,129.58,128.73,128.70,128.60,128.32,128.24,127.62,127.45,126.45,126.30,125.17,122.57,119.93,111.34,110.73,102.01 ,101.46,83.60,80.26,76.70,75.28,74.74,74.71,74.49,71.28,70.86,70.43,69.78,69.58,69.15,58.04,57.41,53.95,49.04,48.99,46.07,43.85,42.93,41.79,38.4 2,36.51,36.15,34.99,34.94,34.36,33.63,32.97,32.15,29.01,28.69,27.47,27.40,27.11,26.76,26.33,25.85,25.73,24.86,22.57,21.35,20.66,20.38,13.90,9.75.
[0143] Example 10
[0144] Phenylpropionic acid, β-(benzoylamino)-α-[4-[3-[3-[2-[3-[1-[5-[methoxypolyethylene glycol aminocarbonyl]pentyl]-1,3-dihydro-3,3-dimethyl-2H-indol-2-methylidene]ethylidene]-2-chloro-1-cyclohexen-1-yl]vinyl]-3,3-dimethyl-5-sulfonic acid-3H-indol-1-ylpropylaminocarbonyl]ethyl]disulfide]butyryloxy-6,12b-bis(acetyloxy)-12-(benzoyl)propionic acid Synthesis of (2aR-[2aα,4β,4aβ,6β,9α(αR*,βS*),11α,12α,12aα,12bα)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methylene-1H-cyclodecano[3,4]benzo[1,2-b]oxetan-9-yl ester, [2aR-[2aα,4β,4aβ,6β,9α(αR*,βS*),11α,12α,12aα,12bα]] (Z-10):
[0145]
[0146] The same synthesis method as that of compound Z-1 in Example 1 was used to react compound 1-8 with compound PTX-4 to obtain Z-10 as a green solid with an amount of 280 mg and a yield of 20.5%. 1 H-NMR (600 MHz, DMSO-d 6 )δ9.23(d,J=8.4Hz,1H),8.26(d,J=13.8Hz,2H),8.04(t,J=5.7Hz,1H),7.99–7.96(m,2H),7.87–7.80(m,4H),7.74(t,J =7.3Hz,1H),7.68–7.62(m,4H),7.54(t,J=7.3Hz,1H),7.48(t,J=7.6Hz,2H),7.45–7.41(m,6H),7.38(d,J=8.4Hz,1H), 7.28(ddd,J=8.0,5.4,2.8Hz,1H),7.18(ddt,J=6.4,4.7,2.2Hz,1H),6.35–6.27(m,3H),5.80(t,J=9.1Hz,1H),5.75(s, 1H),5.52(t,J=8.8Hz,1H),5.41(d,J=7.2Hz,1H),5.36(d,J=9.1Hz,1H),4.90(dd,J=8.4,4.3Hz,2H),4.62(s,1H),4.21( p,J=6.9Hz,4H),4.10(dt,J=11.2,7.0Hz,1H),4.00(q,J=8.3Hz,2H),3.59(dd,J=26.0,6.1Hz,2H),3.52–3.46(m,88H), 3.42(dd,J=5.9,3.7Hz,2H),3.36(t,J=6.0Hz,2H),3.23(s,3H),3.17(dq,J=17.2,6.2Hz,4H),2.72–2.63(m,8H),2.31( qd,J=8.2,5.4,3.4Hz,1H),2.24–2.16(m,5H),2.07(d,J=21.4Hz,5H),1.91–1.81(m,8H),1.78(s,3H),1.72(t,J=7.6Hz ,2H),1.67(s,12H),1.54(t,J=7.5Hz,2H),1.49(s,3H),1.35(q,J=8.0,7.4Hz,2H),1.23(s,1H),1.00(d,J=19.2Hz,6H); 13 C-NMR (151 MHz, DMSO-d 6)δ202.34,172.57,172.18,171.96,171.91,171.52,169.66,169.31,168.77,166.36,165.22 ,148.16,145.85,143.05,142.02,141.99,141.09,140.49,139.31,137.30,134.20,133.52, 133.44,131.50,129.94,129.58,128.73,128.69,128.59,128.33,128.23,127.61,127.43,126.42,126.29,125.19,122.58,119.93,111.33,110.71,101.96,101.50,83.60,80.25,76.6 9,75.27,74.70,74.58,74.48,71.28,70.87,70.41,69.78,69.58,69.15,58.04,57.39,54.92,54.04,49.02,46.06,43.84,42.93,41.81,39.94,39.80,39.66,39.52,39.38,39.24,39.1 0,38.42,37.14,36.50,36.17,36.07,34.99,34.36,33.72,31.58,29.02,27.46,27.40,27.14,26.75,26.32,25.83,25.73,24.86,24.56,23.85,22.56,21.36,20.65,20.39,13.86,9.76.
[0147] Embodiment 11
[0148] Phenylpropionic acid, β-(benzoylamino)-α-[3-[2-[3-[1-[5-[methoxypolyethylene glycol aminocarbonyl]pentyl]-1,3-dihydro-3,3-dimethyl-2H-indol-2-methylidene]ethylidene]-2-chloro-1-cyclohexen-1-yl]vinyl]-3,3-dimethyl-5-chloro-3H-indol-1-ylpropylaminocarbonyl]methyl]thio]acetoxy-6,12b-bis(acetoxy)-12-(benzoyloxy)-2 Synthesis of a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methylene-1H-cyclodecano[3,4]benzo[1,2-b]oxetan-9-yl ester, [2aR-[2aα,4β,4aβ,6β,9α(αR*,βS*),11α,12α,12aα,12bα]](Z-11):
[0149] (1) Preparation of [2-[3-[1-[5-[[methoxypoly(oxy-1,2-ethanediyl)]aminocarbonyl]pentyl]-1,3-dihydro-3,3-dimethyl-5-chloro-2H-indol-2-methylideneethylidene]-2-chloro-1-cyclohexen-1-yl]vinyl]-3,3-dimethyl-1-(3-aminopropyl)-3H-indolium bromide (Compound 1-9)
[0150]
[0151] The same synthesis method as compound 1-7 in Example 1 was used, and 4-chlorophenylhydrazine was used as the starting material to obtain compound 1-9 with a yield of 76.4%. MS (FT-ICR) m / z: 821.539 [M + +H] 2+ .
[0152] (2) Synthesis of Compound Z-11
[0153]
[0154] The same synthesis method as that of compound Z-1 in Example 1 was used to react compound 1-9 with compound PTX-5 to obtain Z-11 as a green solid, with an amount of 280 mg and a yield of 21.5%. 1 H-NMR (600 MHz, DMSO-d 6)δ9.26(d,J=8.3Hz,1H),8.29–8.20(m,3H),8.00–7.97(m,2H),7.86–7.80(m,4H),7.75–7.72(m,1H),7.69–7.63(m,4H),7.52(td,J=7.0,1.4Hz,1H),7.47–7.38(m,9H),7.28(ddd,J=7.9,5.6,2.7Hz,1H),7.17(tt,J=6.5,2.1Hz,1H),6.35–6.28(m,3H),5.81(t,J=9.1Hz,1H),5.53(t,J=8.8Hz,1H),5.40(dd,J=11.2,8.2Hz,2H),4.90(d,J=7.1Hz,2H),4.62(s,1H),4.22(d,J=9.4Hz,4H),4.10(dt,J=10.6,7.1Hz,1H),4.03–3.98(m,2H),3.65–3.56(m,4H),3.52–3.47(m,84H),3.43(dd,J=5.9,3.7Hz,2H),3.37(t,J=6.0Hz,2H),3.25(d,J=12.3Hz,5H),3.21(q,J=7.5,6.6Hz,2H),3.16(q,J=5.9Hz,2H),2.70(t,J=6.0Hz,3H),2.24(s,3H),2.10(s,3H),2.06(t,J=7.3Hz,2H),1.87(dt,J=21.9,6.3Hz,4H),1.79–1.76(m,4H),1.73(t,J=7.5Hz,2H),1.68(s,11H),1.54(q,J=7.5Hz,2H),1.50(s,3H),1.37–1.32(m,2H),1.24(d,J=5.1Hz,1H),1.01(d,J=20.4Hz,6H).; 13 C-NMR(151MHz,DMSO-d 6)δ202.47,172.82,172.20,172.08,169.80,169.56,169.21,168.90,168.76,166. 50,165.37,148.31,146.05,143.29,143.12,142.15,142.11,141.19,140.65,139 .41,137.39,134.29,133.66,133.61,131.61,130.07,129.73,128.88,128.83,128.76,128.42,127.73,127.58,126.61,126.47,125.28,122.72,120.07,111.42,1 10.90,102.19,101.52,83.73,80.38,76.82,75.41,75.26,74.83,74.62,71.42,71.10,70.56,69.92,69.72,69.29,58.18,57.54,54.25,49.20,49.11,46.19,44.0 1,43.06,41.80,38.55,36.63,36.51,35.13,34.47,34.44,32.69,27.62,27.53,27.17,26.90,26.45,25.97,25.87,24.99,22.74,21.48,20.79,20.50,14.00,9.89.
[0155] Example 12
[0156] Phenylpropionic acid, β-(benzoylamino)-α-[3-[2-[3-[2-[3-[1-[5-[methoxypolyethylene glycol aminocarbonyl]pentyl]-1,3-dihydro-3,3-dimethyl-2H-indol-2-methylidene]ethylidene]-2-chloro-1-cyclohexen-1-yl]vinyl]-3,3-dimethyl-5-chloro-3H-indol-1-ylpropylaminocarbonyl]ethyl]thiomethylethylidenethio]propanoyloxy-6,12b-bis(acetoxy)-12-(phenylpropionic acid) Synthesis of (Z-12)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methylene-1H-cyclodecano[3,4]benzo[1,2-b]oxetan-9-yl ester (2aR-[2aα,4β,4aβ,6β,9α(αR*,βS*),11α,12α,12aα,12bα)
[0157]
[0158] The same synthesis method as that of compound Z-1 in Example 1 was used to react compound 1-9 with compound PTX-1 to obtain Z-12 as a green solid with an amount of 280 mg and a yield of 21.2%. 1 H-NMR (600 MHz, DMSO-d 6 ) 1 H NMR(600MHz,)δ9.23(d,J=8.5Hz,1H),8.26(d,J=14.3Hz,2H),8.10(t,J=5.6Hz,1H),7.99–7.97(m,2H),7.8 8–7.80(m,4H),7.76–7.72(m,1H),7.69–7.62(m,4H),7.56–7.52(m,1H),7.49–7.38(m,9H),7.29(td,J=7.1, 1.5Hz,1H),7.19(p,J=4.3Hz,1H),6.35–6.28(m,3H),5.84–5.79(m,1H),5.55(t,J=8.8Hz,1H),5.40(dd,J= 23.1,8.1Hz,2H),4.93–4.89(m,2H),4.63(s,1H),4.22(dt,J=15.3,7.7Hz,4H),4.13–4.08(m,1H),4.01(q,J =8.3Hz,2H),3.60(dd,J=26.3,6.0Hz,2H),3.52–3.48(m,84H),3.43(dd,J=5.9,3.7Hz,2H),3.37(t,J=6.0H z,2H),3.24(s,5H),3.17(q,J=5.9,5.5Hz,2H),2.78–2.68(m,10H),2.35(t,J=7.4Hz,2H),2.23(s,3H),2.08 (d,J=19.9Hz,5H),1.92–1.83(m,4H),1.81–1.76(m,4H),1.73(t,J=7.7Hz,2H),1.69–1.65(m,12H),1.57–1. 52(m,3H),1.50(s,3H),1.45(d,J=1.7Hz,6H),1.38–1.32(m,2H),1.25–1.23(m,1H),1.01(d,J=20.2Hz,6H); 13 C-NMR (151 MHz, DMSO-d 6)δ202.48,172.71,172.31,172.09,171.02,170.61,169.78,169.24,168.91,166.51 ,165.36,148.30,145.98,143.19,142.13,141.22,140.62,139.48,137.38,134.34,1 33.65,133.55,131.61,130.08,129.71,128.85,128.73,128.43,128.37,127.79,127.60,126.57,126.46,125.33,122.72,120.06,111.49,110.85,102.09,101.66,83.73 ,80.38,76.84,75.41,74.85,74.81,74.62,71.42,70.96,70.56,69.92,69.72,69.30,58.19,57.54,55.94,54.15,49.15,49.13,46.21,43.98,43.07,41.95,38.55,36.64 ,36.23,35.35,35.13,34.50,34.15,30.63,30.59,27.60,27.54,27.27,26.89,26.46,26.00,25.96,25.87,25.69,24.99,24.77,22.71,21.50,20.79,20.52,14.04,9.89.
[0159] Embodiment 13
[0160] Phenylpropionic acid, β-(benzoylamino)-α-[3-[2-[3-[2-[3-[1-[5-[methoxypolyethylene glycol aminocarbonyl]pentyl]-1,3-dihydro-3,3-dimethyl-2H-indol-2-methylidene]ethylidene]-2-chloro-1-cyclohexen-1-yl]vinyl]-3,3-dimethyl-5-chloro-3H-indol-1-ylpropylaminocarbonyl]ethyl]thio]propanoyloxy-6,12b-bis(acetoxy)-12-(benzoyloxy) Synthesis of 2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methylene-1H-cyclodecano[3,4]benzo[1,2-b]oxetan-9-yl ester, [2aR-[2aα,4β,4aβ,6β,9α(αR*,βS*),11α,12α,12aα,12bα]] (Z-13)
[0161]
[0162] The same synthesis method as that of compound Z-1 in Example 1 was used to react compound 1-9 with compound PTX-2 to obtain Z-13 as a green solid with an amount of 270 mg and a yield of 20.4%. 1 H-NMR (600 MHz, DMSO-d 6 )δ9.24(d,J=8.6Hz,1H),8.26(d,J=13.8Hz,2H),8.09(t,J=5.6Hz,1H),7.99–7.96(m,2H),7.86–7.80( m,4H),7.73(t,J=7.4Hz,1H),7.68–7.62(m,4H),7.54(t,J=7.3Hz,1H),7.49–7.37(m,10H),7.28(t,J= 6.8Hz,1H),7.20–7.17(m,1H),6.35–6.28(m,3H),5.82(t,J=9.0Hz,1H),5.55(t,J=8.8Hz,1H),5.41(d ,J=7.2Hz,1H),5.36(d,J=8.9Hz,1H),4.92–4.89(m,2H),4.64(s,1H),4.21(dt,J=14.4,7.4Hz,3H),4.1 1(dd,J=10.2,6.1Hz,2H),4.01(q,J=8.3Hz,2H),3.63–3.56(m,2H),3.50(dd,J=6.9,3.7Hz,88H),3.42 (dd,J=5.9,3.6Hz,2H),3.36(t,J=6.0Hz,2H),3.24–3.14(m,9H),2.71(d,J=10.3Hz,7H),2.65(t,J=7.2 Hz,2H),2.33(t,J=7.4Hz,2H),2.23(s,3H),2.10(s,3H),2.06(t,J=7.3Hz,2H),1.91–1.82(m,4H),1.7 8(s,3H),1.67(s,11H),1.52(d,J=27.8Hz,7H),1.37–1.32(m,2H),1.23(s,1H),1.01(d,J=20.6Hz,6H); 13 C-NMR (151 MHz, DMSO-d 6)δ202.49,172.71,172.32,172.10,171.10,170.66,169.79,169.25,168.92,166 .59,165.37,148.29,145.98,143.18,142.14,141.22,140.63,139.51,137.39,13 4.37,133.65,133.54,131.63,130.08,129.72,128.85,128.46,128.37,127.78,127.59,126.58,126.46,125.33,122.71,120.07,111.51,110.85,102.10,101.65, 83.74,80.40,76.84,75.42,74.86,74.81,74.62,71.42,70.96,70.57,69.92,69.72,69.29,58.18,57.55,54.13,49.16,49.14,48.74,46.21,43.98,43.07,41.94 ,38.56,36.64,36.24,35.79,35.13,34.50,34.12,27.61,27.54,27.27,27.01,26.89,26.47,26.08,25.98,25.87,25.00,22.71,21.49,20.80,20.51,14.04,9.90.
[0163] Embodiment 14
[0164] Phenylpropionic acid, β-(benzoylamino)-α-[3-[2-[3-[2-[3-[1-[5-[methoxypolyethylene glycol aminocarbonyl]pentyl]-1,3-dihydro-3,3-dimethyl-2H-indol-2-methylidene]ethylidene]-2-chloro-1-cyclohexen-1-yl]vinyl]-3,3-dimethyl-5-chloro-3H-indol-1-ylpropylaminocarbonyl]ethyl]disulfide]propionyloxy-6,12b-bis(acetyloxy)-12-(benzoyloxy) Synthesis of 2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methylene-1H-cyclodecano[3,4]benzo[1,2-b]oxetan-9-yl ester, [2aR-[2aα,4β,4aβ,6β,9α(αR*,βS*),11α,12α,12aα,12bα]] (Z-14)
[0165]
[0166] The same synthesis method as that of compound Z-1 in Example 1 was used to react compound 1-9 with compound PTX-3 to obtain Z-14 as a green solid with an amount of 250 mg and a yield of 18.9%. 1 H-NMR (600 MHz, DMSO-d 6 )δ9.23(d,J=8.6Hz,1H),8.26(dd,J=13.9,4.4Hz,2H),8.14(t,J=5.6Hz,1H),7.99–7.96(m,2H),7.86–7.80( m,4H),7.73(t,J=7.4Hz,1H),7.69–7.61(m,4H),7.54(t,J=7.4Hz,1H),7.49–7.38(m,9H),7.28(td,J=6.9,6 .2,2.3Hz,1H),7.19(p,J=4.3Hz,1H),6.37–6.27(m,3H),5.82(t,J=9.0Hz,1H),5.56(t,J=8.7Hz,1H),5.41( d,J=7.2Hz,1H),5.37(d,J=8.9Hz,1H),4.92–4.88(m,2H),4.63(s,1H),4.21(q,J=8.4Hz,3H),4.10(dt,J=11 .0,7.0Hz,1H),4.01(q,J=8.3Hz,2H),3.60(dd,J=25.3,6.1Hz,2H),3.52–3.46(m,100H),3.43(dd,J=5.9,3. 6Hz,2H),3.36(t,J=6.0Hz,2H),3.24(s,5H),3.16(q,J=5.8Hz,2H),2.92–2.81(m,6H),2.71(t,J=6.5Hz,3H) ,2.46(t,J=7.1Hz,2H),2.23(s,3H),2.08(d,J=21.7Hz,5H),1.91–1.81(m,4H),1.79(s,4H),1.73(q,J=7.7H z,2H),1.67(d,J=2.2Hz,11H),1.57–1.48(m,7H),1.34(p,J=7.9Hz,2H),1.23(s,1H),1.01(d,J=20.0Hz,6H); 13 C-NMR (151 MHz, DMSO-d 6)δ202.49,172.77,172.26,172.09,170.78,170.28,169.78,169.21,168.92,166.62, 165.37,148.30,146.01,143.25,143.14,142.13,141.21,140.64,139.48,137.35,13 4.37,133.65,133.57,131.63,130.08,129.72,128.87,128.84,128.74,128.46,128.38,127.76,127.59,126.58,126.44,125.31,122.71,120.07,111.47,110.87,102.15 ,101.59,83.73,80.40,76.84,75.42,74.88,74.85,74.62,71.42,71.00,70.57,69.92,69.72,69.29,58.18,57.54,54.09,49.18,49.13,46.21,43.99,43.07,41.93,38.5 6,36.65,36.29,35.13,35.08,34.50,33.77,33.11,32.28,29.15,28.83,27.61,27.54,27.25,26.90,26.47,25.98,25.87,25.00,22.71,21.49,20.79,20.52,14.04,9.89
[0167] Embodiment 15
[0168] Phenylpropionic acid, β-(benzoylamino)-α-[4-[3-[3-[2-[3-[1-[5-[methoxypolyethylene glycol aminocarbonyl]pentyl]-1,3-dihydro-3,3-dimethyl-2H-indol-2-methylidene]ethylidene]-2-chloro-1-cyclohexen-1-yl]vinyl]-3,3-dimethyl-5-chloro-3H-indol-1-ylpropylaminocarbonyl]ethyl]disulfide]butyryloxy-6,12b-bis(acetyloxy)-12-(benzoyloxy) Synthesis of 2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methylene-1H-cyclodecano[3,4]benzo[1,2-b]oxetan-9-yl ester, [2aR-[2aα,4β,4aβ,6β,9α(αR*,βS*),11α,12α,12aα,12bα]] (Z-15)
[0169]
[0170] The same synthesis method as that of compound Z-1 in Example 1 was used to react compound 1-9 with compound PTX-4 to obtain Z-15 as a green solid with an amount of 240 mg and a yield of 18.2%. 1 H-NMR (600 MHz, DMSO-d 6 )δ9.23(d,J=8.4Hz,1H),8.26(d,J=13.8Hz,2H),8.04(t,J=5.7Hz,1H),8.00–7.96(m,2H),7.86–7.80(m,4H),7.74 (t,J=7.3Hz,1H),7.68–7.62(m,4H),7.55(t,J=7.3Hz,1H),7.50–7.42(m,8H),7.39(d,J=8.4Hz,1H),7.29(ddd,J=8 .0,5.4,2.8Hz,1H),7.18(ddt,J=6.4,4.7,2.2Hz,1H),6.35–6.28(m,3H),5.80(d,J=9.2Hz,1H),5.76(s,1H),5.53( t,J=8.8Hz,1H),5.41(d,J=7.2Hz,1H),5.36(d,J=9.1Hz,1H),4.90(dd,J=8.4,4.3Hz,2H),4.62(s,1H),4.21(q,J=7 .3,6.8Hz,3H),4.10(dt,J=11.2,7.0Hz,1H),4.01(q,J=8.3Hz,2H),3.59(dd,J=26.0,6.1Hz,2H),3.52–3.47(m,88 H),3.42(dd,J=5.9,3.7Hz,2H),3.36(t,J=6.0Hz,2H),3.24(s,3H),3.18(dt,J=15.3,6.2Hz,4H),2.73–2.63(m,8H) ,2.23(s,3H),2.19(t,J=7.4Hz,2H),2.10(s,3H),2.06(t,J=7.3Hz,2H),1.91–1.80(m,9H),1.78(s,3H),1.72(t,J= 7.6Hz,2H),1.67(s,12H),1.52(d,J=29.7Hz,6H),1.34(p,J=8.0,7.6Hz,2H),1.23(s,1H),1.01(d,J=19.2Hz,6H).; 13 C-NMR (151 MHz, DMSO-d 6)δ202.48,172.71,172.31,172.09,172.05,171.66,169.80,169.45,168.91,166.50, 165.36,148.30,145.98,143.19,142.15,142.13,141.23,140.63,139.45,137.44,134 .34,133.66,133.58,131.64,130.08,129.71,128.87,128.83,128.73,128.47,128.37,127.75,127.56,126.56,126.43,125.32,122.72,120.07,111.47,110.85,102.09,10 1.64,83.74,80.38,76.83,75.41,74.84,74.72,74.62,71.42,71.01,70.55,69.92,69.72,69.29,58.18,57.53,55.06,54.17,49.16,46.20,43.97,43.07,41.95,38.55,37. 28,36.64,36.31,36.21,35.13,34.49,33.86,31.72,29.16,27.60,27.54,27.28,26.89,26.46,25.97,25.87,25.00,24.70,23.99,22.70,21.50,20.79,20.53,14.00,9.89.
[0171] Application Examples
[0172] The chemical name of MTT is 3-(4,5-dimethylthiazole-2)-2,5-diphenyltetrazolium bromide, which is a yellow dye with a trade name of Thiazole Blue. The MTT method can be used to determine the in vitro cytotoxicity of drugs. The detection principle is that NADPH (reduced coenzyme II) in the mitochondria of living cells can reduce exogenous MTT to water-insoluble blue-purple crystalline formazan and deposit it in the cells, while dead cells do not have this function. Dimethyl sulfoxide can dissolve the formazan in the cells, and its optical density (OD) value is measured at a wavelength of 490nm or 570nm using an ELISA reader. Within a certain range of cell numbers, its optical density value is positively correlated with the live cell index. This patent uses the MTT method to investigate the in vitro anti-prostate cancer activity of the target compounds prepared in the above embodiments. Since paclitaxel has a significant effect on solid tumors such as breast cancer, non-small cell lung cancer, ovarian cancer, and gastric cancer, human breast cancer cell lines MCF-7, human gastric cancer SGC-7901, and human colon cancer HCT-116 were selected to evaluate the anti-tumor effect of the target compound, with paclitaxel as a positive control. The specific operation is as follows: the cells to be passaged are digested to prepare a cell suspension, and the suspension is diluted to an appropriate cell density (3.0×10 4 cells / mL), mix well and add 100μL of cell suspension to each well of a 96-well plate, and culture in an incubator overnight to allow the cells to adhere to the wall. The next day, the drug can be added after the cells have adhered to the wall. Preparation of the solution: First dissolve the drug with methanol, and then dilute it with cell culture medium. Then add 200μL of drug-containing culture medium to each well of the 96-well plate, and set up 4 parallel wells for each concentration; only 100μL of fresh culture medium was added to the control group. Then culture in the incubator for 48h, take out the 96-well plate, aspirate the old culture medium, add 100μL of fresh culture medium to each well, and then add 20μL of 5mg / mL MTT solution to each well, culture in the incubator for 4h, aspirate the culture medium, add 200μL DMSO to each well, and oscillate on an oscillator for 10min to dissolve the formazan. Set the absorption wavelength of the microplate reader to 570nm and measure the absorbance value at this wavelength. Cell Inhibition Rate(%)=(1–A / A c )×100%, where A: absorbance value of the dosing well; A c : Absorbance value of the control well. IC was calculated using GraphPad Prism 5.0 software. 50 .
[0173] The in vitro antitumor activity of the tumor-targeting PEGylated indocyanine dye-coupled paclitaxel prodrug compound based on redox-sensitive bond connection in the present invention was determined, and paclitaxel was used as a positive control. The results are shown in Table 1.
[0174] Table 1 The IC 50 (μM)of test compounds in MCF-7,SGC-7901and HCT-116celllines
[0175]
[0176] As can be seen from the above, the tumor-targeted PEGylated indocyanine dye-coupled paclitaxel prodrug compounds based on redox-sensitive bond connection of the present invention all showed certain cytotoxicity. Whether this cytotoxic property is possessed by the compound itself or the redox-sensitive bond is broken after the compound enters the cell, releasing paclitaxel to exert a cytotoxic effect, it is still unclear because no prodrug compound release study has been conducted; but the preliminary results of the cytotoxicity test show that this design idea deserves further study.
[0177] Among the tested compounds, Z-5 and Z-6 were more active, with IC 50 The value is close to that of PTX, and we speculate that this may be related to the release rate of the original drug of these two compounds. The common structural feature of these two compounds is that the sulfur atoms in the redox-sensitive bond are located at the α-position of the carbonyl group of the ester bond formed by paclitaxel 2'-OH. The bridging bond at this position is not only redox-sensitive, but also easier to break, thereby promoting the dissociation of the ester bond connected to the adjacent carbon, so that the original drug can be released faster; it also shows that the sulfur atoms are located at the α-position of the carbonyl group of the ester bond formed by paclitaxel 2'-OH, which is easier to break than the β-position and γ-position.
Claims
1. A PEGylated indocyanine dye-coupled paclitaxel prodrug compound and a pharmaceutically acceptable salt thereof, characterized in that: The compound has a structure shown in general formula (I): in: R1 is selected from hydrogen, C1-C5 alkyl, sulfonic acid, halogen; R2 is selected from hydrogen, C1-C5 alkyl; X is selected from the following link chains: Y - It is a halogen anion; 1≤m≤5; 2≤p≤6; 1≤n≤45.
2. The PEGylated indocyanine dye-coupled paclitaxel prodrug compound and its pharmaceutically acceptable salt according to claim 1, characterized in that: The compound has a structure shown in general formula (I): R1 is selected from hydrogen, C1-C3 alkyl, sulfonic acid, halogen; R2 is selected from hydrogen, C1-C3 alkyl; X is selected from the following link chains: Y - is bromine or iodine; 1≤m≤5; 2≤p≤6; 1≤n≤45.
3. The PEGylated indocyanine dye-coupled paclitaxel prodrug compound and its pharmaceutically acceptable salt according to claim 2, characterized in that: The compound is Phenylpropionic acid, β-(benzoylamino)-α-[3-[2-[3-[2-[3-[1-[5-[methoxypolyethylene glycol aminocarbonyl]pentyl]-1,3-dihydro-3,3-dimethyl-2H-indol-2-methylideneethyl]-2-chloro-1-cyclohexen-1-yl]vinyl]-3,3-dimethyl-3H-indol-1-ylpropylaminocarbonyl]ethyl]thiomethylethylidenethio]propanoyloxy-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4, 11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7, 11-Methylene-1H-cyclodecan[3, 4]benzo[1, 2-b]oxetan-9-yl ester, [2aR-[2aα, 4β, 4aβ, 6β, 9α(αR*, βS*), 11α, 12α, 12aα, 12bα]]; Phenylpropionic acid, β-(benzoylamino)-α-[3-[2-[3-[2-[3-[1-[5-[methoxypolyethylene glycol aminocarbonyl]pentyl]-1,3-dihydro-3,3-dimethyl-2H-indol-2-methylideneethyl]-2-chloro-1-cyclohexen-1-yl]vinyl]-3,3-dimethyl-3H-indol-1-ylpropylaminocarbonyl]ethyl]thio]propanoyloxy-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4, 11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7, 11-Methylene-1H-cyclodecan[3, 4]benzo[1, 2-b]oxetan-9-yl ester, [2aR-[2aα, 4β, 4aβ, 6β, 9α(αR*, βS*), 11α, 12α, 12aα, 12bα]]; Phenylpropionic acid, β-(benzoylamino)-α-[3-[2-[3-[2-[3-[1-[5-[methoxypolyethylene glycol aminocarbonyl]pentyl]-1,3-dihydro-3,3-di-methyl-2H-indol-2-methylidene]ethylidene]-2-chloro-1-cyclohexen-1-yl]vinyl]-3,3-dimethyl-3H-indol-1-ylpropylaminocarbonyl]ethyl]disulfide]propanoyloxy-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4, 11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7, 11-Methylene-1H-cyclodecan[3, 4]benzo[1, 2-b]oxetan-9-yl ester, [2aR-[2aα, 4β, 4aβ, 6β, 9α(αR*, βS*), 11α, 12α, 12aα, 12bα]]; Phenylpropionic acid, β-(benzoylamino)-α-[4-[3-[3-[2-[3-[1-[5-[methoxypolyethylene glycol aminocarbonyl]pentyl]-1,3-dihydro-3,3-di-methyl-2H-indol-2-methylidene]ethylidene]-2-chloro-1-cyclohexen-1-yl]vinyl]-3,3-dimethyl-3H-indol-1-ylpropylaminocarbonyl]ethyl]disulfide]butyryloxy-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4, 11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7, 11-Methylene-1H-cyclodecan[3, 4]benzo[1, 2-b]oxetan-9-yl ester, [2aR-[2aα, 4β, 4aβ, 6β, 9α(αR*, βS*), 11α, 12α, 12aα, 12bα]]; Phenylpropionic acid, β-(benzoylamino)-α-[3-[2-[3-[1-[5-[methoxypolyethylene glycol aminocarbonyl]pentyl]-1,3-dihydro-3,3-di-methyl-2H-indol-2-methylidene]ethylidene]-2-chloro-1-cyclohexen-1-yl]vinyl]-3,3-dimethyl-5-sulfonic acid-3H-indol-1-ylpropylaminocarbonyl]methylthio]acetoxy-6,12b-bis(acetoxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4, 11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7, 11-Methylene-1H-cyclodecan[3, 4]benzo[1, 2-b]oxetan-9-yl ester, [2aR-[2aα, 4β, 4aβ, 6β, 9α(αR*, βS*), 11α, 12α, 12aα, 12bα]]; Phenylpropionic acid, β-(benzoylamino)-α-[3-[2-[3-[1-[5-[methoxypolyethylene glycol aminocarbonyl]pentyl]-1,3-dihydro-3,3-di-methyl-2H-indol-2-methylidene]ethylidene]-2-chloro-1-cyclohexen-1-yl]vinyl]-3,3-dimethyl-5-sulfonic acid-3H-indol-1-ylpropylaminocarbonyl]methyldisulfide]acetoxy-6,12b-bis(acetoxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7, 11-Methylene-1H-cyclodecan[3, 4]benzo[1, 2-b]oxetan-9-yl ester, [2aR-[2aα, 4β, 4aβ, 6β, 9α(αR*, βS*), 11α, 12α, 12aα, 12bα]]; Phenylpropionic acid, β-(benzoylamino)-α-[3-[2-[3-[2-[3-[1-[5-[methoxypolyethylene glycol aminocarbonyl]pentyl]-1,3-dihydro-3,3-dimethyl-2H-indol-2-methylidene]ethylidene]-2-chloro-1-cyclohexen-1-yl]vinyl]-3,3-dimethyl-5-sulfonyl-3H-indol-1-ylpropylaminocarbonyl]ethyl]thio]methylethylidenethio]propanoyloxy-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a,12b-dodecahydro-4, 11-dihydroxy-4a, 8, 13, 13-Tetramethyl-5-oxo-7, 11-methylene-1H-cyclodecan[3,4]benzo[1, 2-b]oxetan-9-yl ester, [2aR-[2aα, 4β, 4aβ, 6β, 9α(αR*, βS*), 11α, 12α, 12aα, 12bα]]; Phenylpropionic acid, β-(Benzoylamino)-α-[3-[2-[3-[2-[3-[1-[5-[methoxypolyethylene glycol aminocarbonyl]pentyl]-1,3-dihydro-3,3-dimethyl-2H-indol-2-methylidene]ethylidene]-2-chloro-1-cyclohexen-1-yl]vinyl]-3,3-dimethyl-5-sulfonyl-3H-indol-1-ylpropylaminocarbonyl]ethyl]thio]propanoyloxy-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7, 11-Methylene-1H-cyclodecan[3, 4]benzo[1, 2-b]oxetan-9-yl ester, [2aR-[2aα, 4β, 4aβ, 6β, 9α(αR*, βS*), 11α, 12α, 12aα, 12bα]]; Phenylpropionic acid, β-(Benzoylamino)-α-[3-[2-[3-[2-[3-[1-[5-[methoxypolyethylene glycol aminocarbonyl]pentyl]-1,3-dihydro-3,3-di-methyl-2H-indol-2-methylidene]ethylidene]-2-chloro-1-cyclohexen-1-yl]vinyl]-3,3-dimethyl-5-sulfonyl-3H-indol-1-ylpropylaminocarbonyl]ethyl]disulfide]propanoyloxy-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4, 11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7, 11-Methylene-1H-cyclodecan[3, 4]benzo[1, 2-b]oxetan-9-yl ester, [2aR-[2aα, 4β, 4aβ, 6β, 9α(αR*, βS*), 11α, 12α, 12aα, 12bα]]; Phenylpropionic acid, β-(benzoylamino)-α-[4-[3-[3-[2-[3-[1-[5-[methoxypolyethylene glycol aminocarbonyl]pentyl]-1,3-dihydro-3,3-di-methyl-2H-indol-2-methylidene]ethylidene]-2-chloro-1-cyclohexen-1-yl]vinyl]-3,3-dimethyl-5-sulfonyl-3H-indol-1-ylpropylaminocarbonyl]ethyl]disulfide]butyryloxy-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4, 11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7, 11-Methylene-1H-cyclodecan[3, 4]benzo[1, 2-b]oxetan-9-yl ester, [2aR-[2aα, 4β, 4aβ, 6β, 9α(αR*, βS*), 11α, 12α, 12aα, 12bα]]phenylpropanoic acid, β-(Benzoylamino)-α-[3-[2-[3-[1-[5-[methoxypolyethylene glycolaminocarbonyl]pentyl]-1,3-dihydro-3,3-dimethyl-2H-indol-2-methylidene]ethylidene]-2-chloro-1-cyclohexen-1-yl]vinyl]-3,3-dimethyl-5-chloro-3H-indol-1-ylpropylaminocarbonyl]methyl] [2aR-[2aα, 4β, 4aβ, 6β, 9α(αR*, βS*), 11α, 12α, 12aα, 12bα]]; Phenylpropionic acid, β-(benzoylamino)-α-[3-[2-[3-[2-[3-[1-[5-[methoxypolyethylene glycol aminocarbonyl]pentyl]-1,3-dihydro-3,3-dimethyl-2H-indol-2-methylidene]ethylidene]-2-chloro-1-cyclohexen-1-yl]vinyl]-3,3-dimethyl-5-chloro-3H-indol-1-ylpropylaminocarbonyl]ethyl]thiomethylethylidenethio]propanoyloxy-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4, 11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7, 11-Methylene-1H-cyclodecan[3, 4]benzo[1, 2-b]oxetan-9-yl ester, [2aR-[2aα, 4β, 4aβ, 6β, 9α(αR*, βS*), 11α, 12α,12aα, 12bα]]; Phenylpropionic acid, β-(benzoylamino)-α-[3-[2-[3-[2-[3-[1-[5-[methoxypolyethylene glycol aminocarbonyl]pentyl]-1,3-dihydro-3,3-dimethyl-2H-indol-2-methylidene]ethylidene]-2-chloro-1-cyclohexen-1-yl]vinyl]-3,3-dimethyl-5-chloro-3H-indol-1-ylpropylaminocarbonyl]ethyl]thio]propanoyloxy-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7, 11-Methylene-1H-cyclodecan[3, 4]benzo[1, 2-b]oxetan-9-yl ester, [2aR-[2aα, 4β, 4aβ, 6β, 9α(αR*, βS*), 11α, 12α, 12aα, 12bα]]; Phenylpropionic acid, β-(benzoylamino)-α-[3-[2-[3-[2-[3-[1-[5-[methoxypolyethylene glycol aminocarbonyl]pentyl]-1,3-dihydro-3,3-di-methyl-2H-indol-2-methylidene]ethylidene]-2-chloro-1-cyclohexen-1-yl]vinyl]-3,3-dimethyl-5-chloro-3H-indol-1-ylpropylaminocarbonyl]ethyl]disulfide]propanoyloxy-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7, 11-Methylene-1H-cyclodecan[3, 4]benzo[1, 2-b]oxetan-9-yl ester, [2aR-[2aα, 4β, 4aβ, 6β, 9α(αR*, βS*), 11α, 12α, 12aα, 12bα]]; Phenylpropionic acid, β-(benzoylamino)-α-[4-[3-[3-[2-[3-[1-[5-[methoxypolyethylene glycol aminocarbonyl]pentyl]-1,3-dihydro-3,3-dimethyl-2H-indol-2-methylidene]ethylidene]-2-chloro-1-cyclohexen-1-yl]vinyl]-3,3-dimethyl-5-chloro-3H-indol-1-ylpropylaminocarbonyl]ethyl]disulfide]butyryloxy-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7, 11-Methylene-1H-cyclodecan[3, 4]benzo[1, 2-b]oxetan-9-yl ester, [2aR-[2aα, 4β, 4aβ, 6β, 9α(αR*, βS*), 11α, 12α, 12aα, 12bα]].
4. A method for preparing the PEGylated indocyanine dye-coupled paclitaxel prodrug compound and its pharmaceutically acceptable salt according to claim 1, characterized in that: (1) 2,3,3-trimethylindole with substituent R1 and alkylating agent Y-(CH2) m The quaternary ammonium salt 1 was prepared by COOH reaction, and the molar ratio of substituted indole to alkylating agent was 1:1~1:4; (2) 2,3,3-trimethyl-3-substituted indole with a substituent R2 and an alkylating agent Y-(CH2) p The quaternary ammonium salt 2 is prepared by the reaction of NH2·HBr, and the molar ratio of the substituted indole to the alkylating agent is 1:1~1:4; (3) reacting the quaternary ammonium salt 2 obtained in step (2) with Boc anhydride to obtain a quaternary ammonium salt 3, wherein the molar ratio of the quaternary ammonium salt 2 to the Boc anhydride is 1:1 to 1:3; (4) reacting the quaternary ammonium salt 1 prepared in step (1) and the quaternary ammonium salt 3 prepared in step (3) with N-[(3-(anilinomethylene)-2-chloro-1-cyclohexene-1-yl)methylene]aniline hydrochloride 4 to prepare an indole heptamethine cyanine compound 5; (5) Indole heptamethine cyanine compound 5 reacts with methoxy polyethylene glycol amine (PEG-NH2) under the catalysis of a condensation agent to obtain PEGylated indole heptamethine cyanine 6; (6) Indole heptamethine cyanine compound 6 is subjected to removal of the Boc protecting group under acidic conditions to obtain indole heptamethine cyanine 7; (7) indole heptamethine cyanine 7 undergoes condensation reaction with a paclitaxel derivative to obtain a compound having the general structural formula (I); 。 5. The method according to claim 4, characterized in that: In step (1), Y-(CH2)mCOOH is a halogenated carboxylic acid containing 1 to 6 carbon atoms; In the step (2), Y-(CH2) p NH2·HBr is the hydrobromide of a haloalkylamine containing 2 to 6 carbon atoms.
6. The method according to claim 4, characterized in that: The steps (1) and (2) are reacted in the presence of a solvent, the reaction time is 4 to 40 hours, and the reaction temperature is 60 to 148° C.; wherein the solvent is selected from toluene, xylene, dichlorobenzene, ethanol, methanol or acetonitrile.
7. The method according to claim 4, characterized in that: In the step (4), the molar ratio of the quaternary ammonium salt 1, the quaternary ammonium salt 3, and the N-[(3-(anilinomethylene)-2-chloro-1-cyclohexene-1-yl)methylene]aniline hydrochloride 4 is 1:1:1; The step (4) is carried out in a solvent / catalyst system, wherein the solvent / catalyst is ethanol / sodium acetate, and the ratio of the catalyst to the quaternary ammonium salt 1 is 0.3:1 to 3:
1.
8. A pharmaceutical composition, characterized in that: The composition comprises a PEGylated indocyanine dye coupled to paclitaxel prodrug compound represented by the general formula (I) in claim 1, a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
9. Use of the compound according to claim 1, characterized in that: Use of a PEGylated indocyanine dye coupled to paclitaxel prodrug compound represented by general formula (I) and a pharmaceutically acceptable salt thereof or the pharmaceutical composition according to claim 8 in the preparation of anti-tumor drugs.
